Document:

ontario_ex1014.htm

EXHIBIT 10.14
 
COLLABORATION AGREEMENT 
 
THIS COLLABORATIVE RESEARCH AGREEMENT (the "Agreement") is made effective as of December 8, 2011 (the "Effective Date"), by and between the Ontario Brain Institute ("OBI"), Behaviour Neurological Applications and Solutions ("Company"), and The Hospital for Sick Children ("Hospital"), located at 555 University Avenue, Toronto, Ontario, Canada.
 
WHEREAS OBI is a not-for-profit corporation located in Southern Ontario planning to undertake the development and commercialization of technology, as more fully described in this Agreement, in collaboration with other not-for-profit corporations, post-secondary institutions and private sector entities located in Southern Ontario;
 
WHEREAS the Southern Ontario Development Program (SODP) was created to support the Federal Economic Development Agency for Southern Ontario's ("FedDev") mandate to help make Canadians more productive and competitive in a knowledge-based economy, by supporting economic development, economic diversification, job creation, and sustainable, self-reliant communities in Southern Ontario;
 
WHEREAS the Technology Development Program is an initiative of the SODP with the aim of addressing the funding gap between business-driven research and development by encouraging greater collaboration and partnerships between private and public sectors located in Southern Ontario on innovative, game-changing technologies.
 
WHEREAS OBI has entered into a Contribution Agreement ("Contribution Agreement") with the Minister responsible for the Federal Economic Development Agency for Southern Ontario ("Minister") pursuant to which the Minister has agreed to provide a contribution to OBI for its eligible and supported costs of the Projects subject to the terms of this Agreement (as defined below);
 
WHEREAS the OBI has identified 14 projects at research institutes in partnership with the private sector, with potential to accelerate the commercial development of neurotechnology projects founded on Ontario's world-leading academic and clinical research;
 
WHEREAS FedDev will provide funding support to OBI to assist it in achieving its goals and executing the Project described in the Contribution Agreement dated 28 Mach 2012;
 
AND WHEREAS the Hospital and Company of this Project have submitted an application to OBI for funding support as part of The Development of the Ontario Neurotechnology Cluster FedDev application with the Project entitled: "Development of a software based treatment program for ADD/ADHD in children";
 
AND WHEREAS OBI, the Hospital and Company wish to set out in this Agreement their respective understandings, rights and obligations concerning the Financial Contribution from FedDev which will be disbursed through OBI;
 
	  
	1

	  
	  
	  

 
NOW, THEREFORE, in consideration of the premises and mutual covenants contained herein, and intending to be legally bound hereby, the parties hereto agree to the following terms and conditions:
 
SECTION I - Definitions
 
1.1 "Confidential Information" shall mean (a) all information arising out of the Project and (b) all information disclosed by the Disclosing Party to the Receiving Party, whether disclosed orally or in written, graphic or electronic form. In particular, but without limitation, Confidential Information shall include, but not be limited to, the Disclosing Party's scientific, technical and business information such as patent applications, trade secrets, inventions, ideas, procedures, formulations, processes, formulas, data, business plans and strategies, business operations and systems, and information concerning existing and potential employees, customers, strategic partners and licensees. The term "Confidential Information" shall not, however, be deemed to include information that the Receiving Party can demonstrate by competent written proof: (i) is now, or hereafter becomes, through no act or failure to act on the part of the Receiving Party, in the public domain; (ii) is known by the Receiving Party at the time of receiving such information, as evidenced by its records; (iii) is independently developed by or for the Receiving Party by employees or contractors who did not have access to the Confidential Information; or (iv) is hereafter furnished to the Receiving Party by a third party, as a matter of right and without restriction on disclosure.
 
1.2 "Disclosing Party" means any party to this Agreement providing information to any other party to this Agreement.
 
1.3 "Inventor" shall mean an individual who qualifies as an inventor according to the definition of this term under U.S. patent law, and who is employed by Hospital or Company or who is contractually required to assign intellectual property to Hospital or Company.
 
1.4 "Project Intellectual Property" includes, without limitation, all designs, specifications, software, data, drawings, plans, reports, patterns, models, prototypes, demonstration units, practices, inventions, methods and related technology, processes or other information conceived, produced, developed or reduced to practice in carrying out the Project, and all rights therein, including, without limitation, patents, copyrights, industrial designs, trade-marks and any registrations or applications for the same and all other rights of intellectual property therein, including any rights which arise from the above items being treated as trade secrets or confidential information.
 
1.5 "Patent" shall mean any present or future patent or patent application in Canada or elsewhere, any pending patent applications, and any future patent covering the Project Intellectual Property or any part thereof.
 
1.6 "Receiving Party" shall mean a party receiving information from any other party to this Agreement.
 
	  
	2

	  
	  
	  

 
1.7 "Duration of the Contribution Agreement" is 12 months after the earlier of Project Completion date of 31 March 2014 or the completion of the project.
 
1.8 "Control Period" The parties agree that, for the purposes of this Agreement, the "Control Period" means the period of six (6) years following the Duration of the Agreement.
 
SECTION II - Collaborative Research: Term and Termination
 
2.1 The Hospital and Company shall each perform the tasks and activities allocated to the Hospital and Company in Appendix A. The parties acknowledge and agree that Dr. Russell Schachar (the "Investigator") shall have primary responsibility for overseeing the Hospital's role in the Project.
 
2.2 The Company shall devote the cash or in-kind resources to the Project as outlined in the budget included in Appendix A. The Company agrees that the Company Contribution shall be equal to at least fifty percent (50%) of all funding provided to the project through OBI from FedDev, on a combined basis.
 
2.3 OBI shall disburse the Financial Contribution to the Hospital according to the payment terms in the Contribution Agreement and according to the budget included in Appendix A, attached to this Agreement and as OBI receives funds from FedDev. None of the Financial Contribution funds are payable to the Company. The Company will be solely responsible for any cost overruns and funding shortfalls relating to the Project. The Hospital shall submit a Claim Statement (the form of which is attached as Exhibit B) to OBI to be reimbursed for cash expenses incurred, no less frequently than quarterly. Notwithstanding the foregoing, the Hospital may submit Claim Statements as frequently as monthly to allow for a timely reimbursement of cash expenses. The Attestation Form (attached as Exhibit C) must be used for labour expenses. The Company must attest and document that the Company's in-kind Contribution is greater than or equal to the Financial Contribution. As such, the Company is required to submit signed reports to the Hospital within 45 days after the end of each quarter, containing sufficient detail to permit the Hospital to prepare a financial Claim Statement.
 
2.4 The parties acknowledge and agree that according to Section 6.7 of the Contribution Agreement, if any interest is earned by the Hospital as a consequence of any advance payment of funds under the Contribution or if revenue is earned from all or part of the activities supported by the Contribution, FedDev may in its sole and absolute discretion reduce the Contribution by all or by such portion of the revenue (including the interest) as FedDev deems appropriate.
 
2.5 The term of this Agreement shall commence on the Effective Date and shall remain in effect until the expiration or termination of the Contribution Agreement, unless sooner terminated in accordance with Section 2.6 of this Agreement. 
 
2.6 Any party may terminate this Agreement upon thirty (30) days advance notice in the event of default by another party, provided that the defaulting party may prevent termination by curing the default within such thirty (30) day period. For purposes of this Section, a party shall be in default if such party makes a misrepresentation, fails to comply with a term or condition of this Agreement, commits an act of bankruptcy, becomes insolvent, winds-up or is dissolved, ceases or substantially ceases to carry on its business, or sells all or substantially all of its assets. Notwithstanding anything to the contrary in this Agreement, the following sections shall survive termination of this Agreement: Section I, Section 2.2, 2.4, 2.5, 2.6, Section IV, Section VI, Section VII and Section VIII.
 
	  
	3

	  
	  
	  

 
SECTION III - Intellectual Property and Assets
 
3.1 The parties agree that all background intellectual property of a party and all intellectual property of a party that is created during the term of this Agreement that is not Project Intellectual Property remains the property of that party and the other party shall have no right or license to it, except as otherwise specifically set out herein.
 
3.2 All rights and title to Project Intellectual Property shall belong jointly to Hospital and Company. The Hospital and Company shall retain such ownership of Project Intellectual Property for the duration of the Contribution Agreement. Notwithstanding the applicable patent or other intellectual property laws in any jurisdiction, none of the parties may commercially exploit any Project Intellectual Property except as specifically provided for in Section 4.
 
3.3 Each party shall promptly notify the other party=of any Project Intellectual Property that is created during the term of this Agreement. Within 90 days of becoming aware of the creation of Project Intellectual Property, a party shall provide a written notice to the other party providing a detailed description of the Project Intellectual Property. The Company shall ensure that appropriate steps are taken to protect the Project Intellectual Property and shall, upon request, provide information to the Hospital, OBI, and FedDev in this regard.
 
Company may elect to file one or more Patents relating to such Project Intellectual Property, in which case Company shall promptly prepare, file, and prosecute such Patents in such jurisdictions as Company determines in the joint names of Hospital and Company. Company shall bear all costs incurred in connection with the preparation, filing, prosecution, and maintenance of such Patents. If Company does not elect to file one or more Patents within the Option Period (defined below), Hospital may elect to file one or more Patents relating to such Project Intellectual Property, in which case Hospital shall promptly prepare, file, and prosecute such Patents in such jurisdictions as Hospital determines in the joint names of Hospital and Company.
 
3.4 Company shall cooperate with Hospital to ensure that all Patents it files cover, to the best of Company's knowledge, all items of commercial interest and importance. While Company shall be responsible for making final decisions regarding the scope and content of those Patents and the prosecution thereof, Company shall keep Hospital informed of all material developments regarding those Patents, shall provide Hospital with copies of all Patents and related documents, and shall provide Hospital with a reasonable opportunity to comment on all material documents relating to the Patent process. Company shall promptly provide Hospital with copies of any issued Patents, as well as related serial numbers and filing dates.
 
	  
	4

	  
	  
	  

 
3.5 If any party intends to file a patent application on subject matter that is related in any way to the Project but does not constitute Project Intellectual Property covered by this Agreement, that party shall give notice to the other party, at least 30 days prior to filing its patent application, of the basic subject matter of the patent application, the claims being made in the patent application and the names of the inventors on the patent application.
 
3.6 In accordance with Section 14.1 of the Contribution Agreement, the Hospital shall retain title to, and ownership of any assets (excluding Project Intellectual Property), the cost of which has been contributed to by FedDev under the Contribution Agreement and shall not sell, assign, transfer, encumber, pledge, grant a security interest or otherwise dispose of same, without the prior written consent of FedDev. If such assets are jointly owned by the Hospital and Company as a result of the sharing of acquisition costs, this Section will apply only to the portion owned by Hospital.
 
3.7 In accordance with Section 14.2 of the Contribution Agreement, any assets (other than Project Intellectual Property) the cost of which has been contributed to by FedDev under the Contribution Agreement may be owned by the Hospital, provided that for the duration of the Contribution Agreement and the Control Period (as defined in the Contribution Agreement) the Hospital will not sell, assign, transfer, encumber, pledge, grant a security interest or otherwise dispose of such assets other than in a manner set out in Subsection 14.1 of the Contribution Agreement.
 
SECTION IV - Grant of Rights
 
4.1 Hospital hereby grants to Company the option to obtain (the "Option") an exclusive, world-wide, perpetual, royalty-bearing license to use or otherwise exploit Hospital's interest in Project Intellectual Property, subject to terms and conditions determined in accordance with this Section 4 under reasonable licensing terms. The option shall exist for a period of 12 months after written disclosure of the Project Intellectual Property (the "Option Period"). The Option may be exercised within the Option Period by Company delivering written notice to Hospital (the "Option Exercise Notice").
 
4.2 If Company exercises the Option, the parties shall negotiate in good faith to determine the specific terms and conditions on which the license shall be granted by Hospital to Company.
 
4.3 If Company obtains a license to Project Intellectual Property pursuant to this Agreement and reasonably requires the ability to use or otherwise exploit Hospital's intellectual property that is not also Project Intellectual Property, Hospital shall grant a license to use or otherwise exploit such intellectual property, if available, to the extent required for Company to use or otherwise exploit the Project Intellectual Property, and such license shall be negotiated to contain mutually acceptable terms, including but not limited to a term requiring the payment of consideration over and above the royalties applicable to the Project Intellectual Property.
 
	  
	5

	  
	  
	  

 
4.4 Notwithstanding the above, each party retains the following rights with regard to the Project Intellectual Property:
 
(a) Each party retains an internal-use license, strictly for research and educational purposes, to all Project Intellectual Property; and
 
(b) In the absence of the execution of an exclusive license of Hospital's interest in any Project Intellectual Property to Company, the parties will not sell, assign, transfer, license or exploit the Project Intellectual Property or their interests therein unless and until the parties have executed an agreement allocating between the Hospital and Company any revenue, remuneration, or consideration that may be derived from using, commercializing or otherwise exploiting Project Intellectual Property.
 
4.5 No exclusive and irrevocable license to the Project Intellectual Property will be granted and no sublicense will be granted except where the Hospital receives royalties directly or indirectly from the sublicense or whereby the licensee of an exclusive and irrevocable license has compensated the Hospital in a minimum amount of the Contribution.
 
SECTION V - Patent Infringement
 
5.1 If either Company or Hospital should learn of the infringement of any Patent, that party shall promptly notify the other party in writing of the existence of the infringement and shall provide as much detail about the nature of the infringement as is available to that party. Company, in cooperation with Hospital, shall use its best efforts to eliminate such infringement without litigation. If the efforts of the parties are not successful in eliminating the infringement within 30 days after the infringer has been formally notified of the infringement, either party to this Agreement shall have the right to:
 
(a) commence suit on its own account;
 
(b) join with the other party in such suit;
 
(c) join with any licensee(s) in such suit; or
 
(d) refuse to participate in such suit by giving written notice to the other party within 30 days or notice by such other party of its intention to commence suit.
 
Company may permit its licensee(s) to bring suit on its own account and participate in such suit with such licensee(s), but only if Company and Hospital elect not to commence separately or join each other in any suit, other than as a nominal party plaintiff, either by formal notice or by failure to act within the above referenced 30 days for giving written notice.
 
	  
	6

	  
	  
	  

 
5.2 The expenses for any legal action instituted under Section 5.1 shall be paid for by the party or parties filing the litigation. If either party elects not to join the litigation, that party shall not have to pay any related legal expenses, and that party shall not be entitled to any proceeds from the litigation. If, however, the parties jointly file the litigation (or one party joins the litigation after the other party has filed it), the parties shall agree to an allocation of litigation expenses and proceeds within 90 days of joining together in the litigation.
 
5.3 Each party agrees to cooperate with the other in litigation proceedings instituted hereunder at the expense of the party on account of whom suit is brought if brought solely for one party's account. The party bringing suit shall control such litigation (including the settlement thereof), except that Company shall control the suit if brought jointly. Hospital may be represented at its expense by counsel of its choice in any suit brought solely by Company or its licensee(s).
 
SECTION VI -Confidential Information
 
6.1 Each Receiving Party agrees, during the term of this Agreement and for five years after this Agreement is terminated:
 
(a) to hold Confidential Information in confidence and to take reasonable precautions to protect the same (including, without limitation, all precautions such party employs with respect to its own confidential information);
 
(b) not to divulge any such Confidential Information to any third party (except consultants approved in writing by the Disclosing Party, provided that such consultants agree to be bound by confidentiality provisions at least as restrictive as those contained in this Section VI);
 
(c) not to make any use whatsoever at any time of such Confidential Information except for the purpose of performing the party's obligations under this Agreement;
 
(d) not to use any such Confidential Information as the basis for beginning any new research and development programs; and
 
(e) not to copy or reverse engineer any such Confidential Information.
 
6.2 Notwithstanding any other provision of this Agreement, disclosure of Confidential Information shall not be prohibited if such disclosure: (i) is necessary to fulfill Company's responsibilities with respect to managing any Patents; (ii) is in response to a valid order of a court or other governmental body of Canada or any political subdivision thereof; provided, however, that the Receiving Party shall first have given notice to the Disclosing Party and shall have made a reasonable effort to obtain a protective order requiring that the Confidential Information so disclosed be used only for the purposes for which the order was issued; (iii) is otherwise required by law, or (iv) consists of OBI disclosing Confidential Information to FedDev, or any other government agency or authority.
 
	  
	7

	  
	  
	  

 
6.3 At the conclusion of this Agreement, each party shall either return the other's Confidential Information in its possession (including all copies) or shall, at the Disclosing Party's direction, destroy such Confidential Information (including all copies) and certify its destruction to the Disclosing Party.
 
6.4 In the course of performing the Project, Hospital and Investigator may collect personal information or personal health information, as those terms are defined in Canada's Personal Information Protection and Electronic Documents Act, S.C. 2000, c.5 ("PIPEDA") and Ontario's Personal Health Information Protection Act ("PHIPA") (the "Privacy Laws"), from patients/subjects. In the event that personal information or personal health information about a Study Subject (collectively "PHI") is transferred to the Company and/or OBI including their employees, authorized representatives or agents, the Company, OBI and their employees, authorized representatives and agents shall comply with the Privacy Laws and, specifically, shall not use or disclose such PHI except as expressly permitted in relevany informed consent forms or as required by law. Such PHI shall be appropriately protected against misuse by the Company and OBI and shall be retained only as long as necessary for fulfillment of the approved purpose for which it was collected. The obligations of this section shall survive the termination of this Agreement.
 
SECTION VII - Publications
 
7.1 The Hospital and the Company shall collaborate in preparing and submitting a joint publication of the results of the Project, and neither the Hospital or the Company shall publicly present, orally or in writing, any results of the Project prior to such joint publication without the consent any other party.
 
7.2 Notwithstanding the above, if the Hospital and the Company have an irreconcilable dispute as to the content or timing of the joint publication, or if the Hospital or the Company desires to publicly present results of the Project and any other party will not consent to such presentation, where each party has negotiated in good faith, either the Hospital or the Company may publish or present individually the results of the Project, provided however that:
 
(a) the Hospital or the Company intending to publish or present (the "Presenting Party") shall provide to the Hospital or the Company not intending to publish or present (the "Nonpresenting Party"), as soon as possible, but in any event at least 60 days prior to submission to a journal, editor, or other third party, copies of any proposed publication or presentation; and
 
(b) the Nonpresenting Party has not, within 30 days after receipt of said copies, objected in writing to such proposed presentation or proposed publication in accordance with Article 7.3 of this Agreement.
 
	  
	8

	  
	  
	  

 
7.3 The Nonpresenting Party may object to a proposed presentation or proposed publication of the other party on the grounds that it contains Confidential Information of the Nonpresenting Party or on the grounds that it discloses patentable subject matter relating to Project Intellectual Property. If the Nonpresenting Party makes such objection on the former ground, the Presenting Party shall ensure that its researchers remove such Confidential Information immediately from the proposed presentation or publication, after which the Presenting Party and its representatives may proceed with said presentation or publication. If the Nonpresenting Party makes an objection on the latter ground, it shall be deemed an election by the Nonpresenting Party to file a Patent pursuant to Section 3.3, and the Presenting Party shall ensure that its representatives refrain from making such publication or presentation until the earlier of: (a) the date the Nonpresenting Party has filed one or more Patents with one or more patent offices directed to such patentable subject matter, or (b) the later of the expiration of the Option Period or 90 days after receipt of such written objection from the Nonpresenting Party.
 
7.4 All of this Section VII shall be subject to Section 8.12 Publicity.
 
SECTION VIII - Miscellaneous
 
8.1 Government Requirements and Compliance. Each party shall comply with all federal, provincial, territorial, municipal, and other applicable laws, regulations, by-laws, rules, decrees and ordinances governing the parties and the Project, including without limitation, environmental legislation and any mitigation measures imposed by FedDev, as well as all relevant laws, regulations, standards and policies regarding research subject protection and the ethical conduct of research, including the Tri-Council Policy Statements: Ethical Conduct for Research Involving Humans.
 
8.2 Notices. Any notice under any of the provisions of this Agreement shall be deemed given two days after being deposited in the mail, postage prepaid, registered or certified first class mail and addressed to the applicable party at the address stated on the signature page hereof, or such other address as such party shall specify for itself by like notice to other party. All notices shall be in writing and be signed by an authorized representative. Either party may change such address by notice given to the other party in the manner set forth above. Notice shall be given to the parties at the addresses listed below:
 
If from Company to Hospital:
 
For scientific or technical issues:
The Hospital for Sick Children
Department of Psychology
Dr. Russell Schachar
555 University Ave
Toronto, Ontario M5G 1X8
 
	  
	9

	  
	  
	  

 
For financial issues:
The Hospital for Sick Children
Grants Management Office
555 University Ave
Toronto, Ontario M5G 1X8
 
For legal, intellectual property or technology transfer issues:
The Hospital for Sick Children
Director of Legal Services
555 University Ave
Toronto, Ontario M5G 1X8
 
If from Hospital to Company:
 
Neil J. Closner
110 Eglinton Avenue West. Suite 401
Toronto, Ont. M4R 1A3
 
8.3 Governing Law. This Agreement will be governed by the laws of the Province of Ontario and the laws of Canada applicable therein.
 
8.4 Independent Contractors. The relationship of the parties to this Agreement shall be that of independent contractors. Each party shall maintain sole and exclusive control over its personnel and operations.
 
8.5 Use of Name or Endorsements. By entering into this Agreement, neither party shall be deemed to directly or indirectly endorse any product or service provided, or to be provided, whether directly or indirectly related to either this Agreement or to any patent or other intellectual property license or agreement that implements this Agreement by its successors, assignees, or licensees. Neither party shall in any way state or imply that this Agreement is an endorsement of any such product or service by the other party. Neither party shall be authorized to use the name(s) and/or logo(s) of the other party for publicity and marketing without the written consent of such party.
 
8.6 Reasonable Consent. Whenever a party's consent or permission is required under this Agreement, such consent or permission shall not be unreasonably withheld.
 
8.7 Dispute Resolution. All disputes arising out of or relating to this Agreement shall be resolved using the following procedure:
 
(a) Negotiation. The parties shall attempt in good faith to resolve any dispute arising out of or relating to this Agreement promptly between officials who have authority to settle the controversy.
 
(b) Mediation. If the matter had not been resolved by negotiation within 30 days, the parties shall then attempt in good faith to settle the dispute by mediation.
 
	  
	10

	  
	  
	  

 
(c) Arbitration. If the matter had not been resolved by mediation within 90 days of the initiation of such procedure, or if either party did not wish to participate in a mediation, the dispute shall then be settled by arbitration in accordance with Ontario's Arbitration Act, 1991.
 
(d) Location. The parties agree that any mediation or arbitration shall be held in a mutually convenient location.
 
8.8 Records and Audits.
 
(a) The parties will maintain proper and accurate accounts and records in relation to the Project for at least six (6) years after the Date of Completion (as defined in the Contribution Agreement), and will maintain a copy of all records relating to the Project in a location in Southern Ontario. Such records shall include, without limitation:
 
	  	i)
	Invoices, which should include details of what is being invoiced (product/service), and clear information on what created the value shown on the invoice (e.g. product specificationss, itemized breakdowns, etc);

	  	  	  
	  	ii)
	Pay stubs, which should align with expenses/contributions appropriately;

	  	  	  
	  	iii)
	Bank records evidencing payment;

	  	  	  
	  	iv)
	Third party proof of payment;

	  	  	  
	  	v)
	Project activity tracking documents. E.g. reports generated by project management software;

	  	  	  
	  	vi)
	Accounting / financial records;

	  	  	  
	  	vii)
	Delivery slips demonstrating receipt of goods; and

	  	  	  
	  	viii)
	Relevant photographs.

 
(b) The parties agree and acknowledge that FedDev and/or the Auditor General of Canada may have access to all accounts and records of the Project (including those of agents and third party contractors) and audit, or cause to have audited, such accounts and records as per Subsection 7.9 of the Contribution Agreement.
 
(c) The parties agree and acknowledge that FedDev may make site visits and access all records or documents relating to the Project in order to monitor and evaluate the Project in accordance with Section 7 and Subsection 11.3 of the Contribution Agreement.
 
	  
	11

	  
	  
	  

 
(d) The Hospital and Company will provide OBI with progress reports on a quarterly basis no later than the 15th business day following the end of each quarter - March 31, June 30, September 30, and December 31, of each year, based on Annex 4 of the Contribution Agreement (Exhibit D of this Agreement) during the course of the Project in order for OBI to meet its obligation to send progress reports to FedDev no later than the 20th business day following the end of the quarter to which the report relates. The Hospital and Company will provide OBI with a final report no later than the two months following the end of the final quarter of the Project, March 31,2014, based on Annex 5 of the Contribution Agreement (Exhibit E of this Agreement) in order for OBI to meet its obligation to send progress reports to FedDev. The Hospital and the Company must both sign each progress report required by this Section.
 
(e) The Hospital and the Company will provide a financial report outlining all costs incurred and the amount of the Company's Contribution no later than ninety (90) days after the end of each fiscal year ending March 31. The Hospital will be responsible for reporting all costs incurred that are covered by the Financial Contribution and the Company will be responsible for reporting the amount and value of the Company's Contribution.
 
8.9 Insurance. The Hospital shall maintain for the duration of the Project general liability insurance and property damage insurance in amounts consistent with the scope and investments of the Project conducted at the Hospital's location, and will include no less than $2,000,000 for general liability insurance. The Hospital will provide endorsements on the property damage insurance naming "Her Majesty the Queen in Right of Canada" as "co-loss payee" and OBI as their interest may appear and endorsements to the liability insurance naming "Her majesty the Queen in Right of Canada" and OBI each as "additional insured". The parties acknowledge and understand that the Hospital's general liability insurance does not cover the clinical activities of physicians, including the Investigator. The parties agree that in the event that any claim arises from the clinical activities of the Investigator, their sole recourse will be against the Investigator. The Investigator will be independently responsible for maintaining coverage through the Canadian Medical Protective Association during the term of this Agreement.
 
8.10 Tendering. The Hospital will adhere to its applicable tendering and acquisition policies for the purposes of the Project.
 
8.11 Change of Control. The Company will provide prior notice to the Hospital and OBI at least 15 days prior to the implementation of any Change of Control (as defined in the Contribution Agreement), providing OBI the right, at its sole discretion, to terminate this Collaboration Agreement if such event occurs.
 
8.12 Publicity. The parties acknowledge that all announcements, ceremonies, and other communications activities related to the Project shall be consistent with the provisions of Section 9 of the Contribution Agreement. Specifically, in this context, the parties will:
 
a. acknowledge OBI and Her Majesty's participation;
 
b. agree to public announcements of the Project by or on behalf of the Minister in the form of a news release;
 
c. maintain confidentiality of this Agreement until the Minister informs the parties of the date of the public announcement;
 
d. agree to the participation of the Minister to any announcement event of the Project organized by the parties and ensure that the event takes place at a mutually agreeable date;
 
	  
	12

	  
	  
	  

 
e. agree to a media/public event upon the completion of the Project with the Minister at a mutually agreeable venue, time, and date; and
 
f. agree to display promotional material provided by the Minister.
 
8.13 Funding to OBI Terminated. Notwithstanding any other term of this Agreement, OBI may terminate this Agreement immediately or any time during in the event that FedDev or the Ontario Provincial Government or any agency or subdivision thereof at any time suspends, revokes or terminates funding to OBI in whole or in part or indicates its intention to do so and OBI is then unable or anticipates that it will in the future be unable to provide its contributions, or satisfy any obligations, contemplated by this Agreement. In such instance OBI will meet its obligation to dispurse funds received from FedDev for already incurred expenses, but will be released from all of its forward obligations and will not be liable for any damages arising from any failure to fund.
 
8.14 Limitation of Liability. In no event shall OBI be liable to another party hereto for any special, indirect, incidental, consequential, or punitive damages of any kind or nature whatsoever, including loss of profits or revenue, howsoever caused, even if such damages are foreseeable or such party has been advised of the possibility of such damages. Furthermore, OBI's total liability to another party hereto in the aggregate for any and all claims arising out of or in any connection with this Agreement, with respect to any expense, damage, loss, injury, or liability of any kind or nature whatsoever, regardless of the form of action or theory of liability (including for breach of contract, tort, negligence, by statute or otherwise) will be limited to the total amount of funds actually disbursed by OBI under this Agreement. Noteithstanding the foregoing, the limitation of liability set forth in this section will not apply to any damage, claim, expense, loss, injury or liability caused by OBI's gross negligence or intentional misconduct.
 
8.15 Overpayment or Non-entitlement. Where, for any reason, the Hospital or the Company is not entitled to all or part of the Financial Contribution, or the amount paid to the Hospital or the Company exceeds the amount to which they are entitled under this Project, the Financial Contribution or the amount in excess shall be recovered from the recipients. The Hospital and the Company agree to repay OBI within thirty (30) calendar days from the date of OBI's notice the amount of the Financial Contribution disbursed or the amount of the overpayment, as the case may be, together with interest calculated in accordance with the Interest and Administrative Charges Regulations, in effect on the due date, from the date of notice, until payment is received by OBI.
 
8.16 Counterparts and Execution bv Facsimile. This Agreement may be executed in one or more counterparts each of which when so executed shall be deemed to be an original and such counterparts together shall constitute but one and the same instrument. Delivery of an executed copy of a signature page to this Agreement by facsimile or electronic transmission shall be effective as delivery of a manually executed copy of this Agreement and each party hereto undertakes to provide each other party hereto with a copy of the Agreement bearing original signatures forthwith upon demand.
 
	  
	13

	  
	  
	  

 
IN WITNESS WHEREOF, the parties hereto have duly executed this Agreement effective as of the date first written above. 
 
	THE HOSPITAL FOR SICK CHILDREN:

	  
	
	  
	BEHAVIOUR NEUROLOGICAL APPLICATIONS AND SOLUTIONS:

	  
	
	  
	ONTARIO BRAIN INSTITUTE:

	  
	
	  
	The Investigator hereby acknowledges that he has read and understands the content of this Agreement and understands the scope if his role in the Project as described in Appendix A

	  
	

 
	  
	14

	  
	  
	  

 
EXHIBIT A; PROJECT PLAN AND BUDGET
 

 
 
 
 

 
 
 
 
 
	  
	15

	  
	  
	  

 
Project Outline
 
	Project Name
	Development of a Software Based Treatment program for Children with ADD/ADHD

	Project Address
	110 Eglinton Ave West Suite 401, Toronto, Ontario M4R 1A3

	Total Project Cost
	$ 1,623,384

	Prviate Sector Investment
	$ 1,132,180

	FedDev Contribution
	$ 491,204

	Other Contribution (if any)
	$0

	Duration of project (months)
	29 months

 
	Not-For-Profit Partner
	Hospital For Sick Children

	Address
	555 University Avenue, Toronto, Ontario, M5G 1X8

	Role in Project
	Oversee clinical study, review and report results

	Cash Investment
	n/a

	In-kind Investment
	n/a

	Total Investment
	$0
	% of Total Budget: 0%

 
	Private Sector Partner #1
	2304101 Ontario Inc., d/b/a Behavioural Neurological Applications and Solutions ("BNAS")

	Industry Sector
	Healthcare software

	Address
	110 Eglinton Ave West Suite 401, Toronto, Ontario M4R 1A3

	Role in Project
	Lead commercial partner, project management, software development, IP holder

	Cash Investment
	  
	In-kind Investment
	$1,132,180

	Total Investment
	$1,132,180 million
	% of Total Budget: 70%

 
Project Description:
 
(THIS ANSWERS THE "WHAT" AND "WHY" OF THE PROJECT)
 
	  	-
	What is the project? Describe the product/technology to be developed.

	  	  	The overall objective of this undertaking is to develop the world's first comprehensive diagnosis, therapeutic and reporting software tool for the treatment of childhood ADD/ADHD. With the assistance of Dr. Russell Schachar and the Hospital for Sick Children, BNAS Inc., leveraging prior intellectual property licenced from ACE Ltd. of Hod HaSharon, Israel, hopes to design and begin marketing this offering within the next 24-30 months.

 
	  
	16

	  
	  
	  

 
	  	-
	What will the technology do and how will it work?

	  	  	The software is intended to offer an objective diagnosis of ADD/ADHD in children, deliver a software based gaming tool for the therapeutic treatment of this condition and a comprehensive reporting engine customized for the various stakeholders.

	  	  	  
	  	-
	Why is the project being undertaken (what need will be filled)?

	  	  	Currently there is no test available on the market that objectively tests for ADD/ADHD. The process today is highly subjective and a number of various methods are utilized by physicians and therapists. Additionally, the market lacks a comprehensive, user friendly and engaging software based program for children to treat ADD/ADHD. The goal is to create a game for children that is both engaging and therapeutic.

 
 Economic Impact
 
	1. How many person-months of employment are expected to be created during the project?
	145

	2. How many FTEs are expected to be created during the project?*
	8

	3. How many FTEs are expected to be created or maintained within 3 years after the project?*
	20+

	4. What is the expected FedDev cost per permanent job created?**
	Approx. $25k

	5. What is the ratio of private sector funds leveraged vs. the FedDev contribution?**
	2.5:1

	6. # of partnerships expected to be established between NFPs and/or PSIs and private sector enterprises during the project:
	2

	7. # of partnerships expected to be established between NFPs and/or PSIs and private sector enterprises within 3 years after the project:
	5

	8. # of innovations expected to be advanced during the project and within 3 years after the project...
        -# of invention disclosures:
        -# of patent applications:
	Unclear

	9. Non-manufacturing company start-ups (#): Manufacturing start-ups: Other (please describe):
	1 non- manufacturin g start-up

	10. What % of activities will take place in Southern Ontario?
	80%

	11. What % of the budget will be spent in Southern Ontario?
	Over 90%

 
Sales Projections (during the project and for each of the 3 years following the project)
 
	 	 
	2012
	 
	 
	2013
	 
	 
	2014
	 
	 
	2015
	 
	 
	2016
	 
	 
	2017
	 

	Users
	 
	 
	-	 
	 
	 
	-	 
	 
	 
	-	 
	 
	 
	30,000	 
	 
	 
	100,000	 
	 
	 
	225,000	 

	 	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 

	Revenues
	 
	 
	-	 
	 
	 
	-	 
	 
	 
	-	 
	 
	$	1,500,000	 
	 
	$	5,000,000	 
	 
	$	11,000,000	 

 
	  
	17

	  
	  
	  

 
Budget Details
(THIS ANSWERS THE "WHAT ARE WE PAYING FOR" AND "WHEN" QUESTION)
 
	  	-
	Where did the numbers come from? (e.g. supporting documentation such as quotes, detailed breakdowns)

	  	  	  
	  	-
	What costs are included within each line item? Eligibility must be determined for anticipated costs

	  	  	  
	  	-
	How were they calculated? For example:

 
	  	·
	Labour and Operating = X number of people at Y salary with Z benefits; X space at Y rate, etc.

	  	  	  
	  	  	Research Assistant = 1 @ $46,350 (annual salary) with 20% benefits of $9,270
Post Doctoral Student = 1 @ $60,000 (annual salary) with 20% benefits of $12,000
Medical Advisor = 1 @ $15,504 (annual salary) with 20 % benefits of $3,100 (based on $150/hr for 2 hours per week/year)

	  	  	  
	  	·
	Equipment = What equipment, what cost, used? New? For what duration? Usage costs or full value?

	  	  	  
	  	  	Equipment purchased for this project will include the purchase of a few new computers and some new computer tablets (i.e. iPads) and related/necessary software for employee use and for design and testing of the application on children. We are including the full value in our budget as these devices become obsolete within 2 years.

	  	  	  
	  	  	We have also included a modest budget amount for Materials and Supplies of $7,890. This will cover minor office supplies and the purchase of some third-party reports necessary for our user trials.

	  	  	  
	  	· 
	Professional Services = How many consultants for what purpose at what rate for how long;

	  	  	  
	  	  	Due to the unique nature of this project (modification and enhancements being made to proprietary software) which goes beyond the typical work conducted at HSC, a contractor(s) will be engaged to undertake the design and development of the software code/product as well as the procurement, operation and disposal of necessary hardware and software in order to complete this successfully. The total amount of the grant allocated for these purposes is projected to amount to $181,380. The direct labour portion will amount to $142,120, which is comprised of a 20% allocation of a project manager's time based on an annual salary of $90,000 plus 17% benefits and $100,000 of total software designer/programmer time at $125/hr for 33 hours per month (the actual number of hours per month will be closer to 140 hours).

 
	  
	18

	  
	  
	  

	  	  	  
	  	·
	Commercialization costs = description of exactly what this includes, how much... should be broken down (not grouped together) for us to determine eligibility;

	  	  	  
	  	  	There are no explicit commercialization costs included in our budget. These costs will be entirely born by BNAS.

	  	  	  
	  	·
	Admin = what expenses does this include, how much, etc.

	  	  	  
	  	  	The only admin costs that we have included are those that are being remitted to the Ontario Brain Institute. This total amounts to $23,358.

 
	  	-
	Everything should be broken down into quarters and fiscal year.

 
	  
	19

	  
	  
	  

 
Milestones and Activities
 
The estimation of the cost for each milestone is exceedingly difficult to arrive at given the variables that we may encounter during this project. We have estimated to the best of our ability but please understand that there is no way to do this with exact figures.
 
	Milestone/deliverable
(what will be delivered
once the activity(ies) is/are done?)
	Activities
(What will be done?)
	Objective/Purpose
(Why do it? How does it relate to
theultimate project goal?)
	Start
Date
	End Date
	Cost (Milestone/ deliverable level)
	Parties Executing
each Activity
	Level of Completion (%)
	Are you on
schedule?
(Yes/No)

	Feasibility and Efficacy Study on original IntelligymTM
	-Establishment of project road map
-Design efficacy study parameters
-Procurere quired equipement(software/hardware)
-hire post doc student and research assistant
	Before designing anything new we must adequately understand the limitations of the existing platform. To do this we must undertake a careful study of the existing system with a cohort of our target demographic
	Dec. 2011
	May 2012
	FedDev: $70,332 BNAS: $265,308
	HSC
BNAS
	  	  
	  	  	  	  	  	  	  	  	  
	Planning the development phase of a new IntelligymTM Including determination of appropriate tasks, cognitive mapping,
	Task mapping matrix and translation documentation Completion of Alpha of new IntelligymTM
	Intensive design/development phase for new program. Will involve physicians, computer programmers, software engineers and game developers.
	May 2012
	December
2012
	FedDev: $144,180 BNAS: $204,361
	HSC
BNAS
	  	  
	  	  	  	  	  	  	  	  	  
	Development of user interface and beta population assembly.
	Design active game play elements of new IntelligymTM Enroll beta population for testing of new IntelligymTM
	Once the cognitive elements are in place it is crucial that we design a game that children will "want" to play
	Nov. 1 2012
	June 2013
	FedDev: $90,259 BNAS: $193,538
	HSC
BNAS
	  	  

 
	Undertake a 60 person randomized clinical trial on new version of IntelligymTM
	First step of validation of new product using new game vs. placebo
	Test new product for efficacy
	June
2013
	Sept 2013
	FedDev: $70,972 BNAS: $189,931
	HSC
BNAS
	  	  
	  	  	  	  	  	  	  	  	  
	Undertake another 100 person trial to test the effectiveness of the new product vs. control group
	Validate the product again a control group that is interacting with another type of computer video game
	Test new product for effectiveness
	October
2013
	January
2014
	FedDev: $52,479 BNAS: $151,223
	HSC
BNAS
	  	  
	  	  	  	  	  	  	  	  	  
	Final modifications and release of IntelligymTM li (final version)
	Complete product
	Project Completion
	January
2014
	March
2014
	FedDev: $39,636 BNAS: $127,823
	BNAS
	  	  

 
	  
	20

	  
	  
	  

 
Project Budget and Timing
 
	 	 
	   Total Project
	 

	 	 
	FedDev -
to SK
	 
	 
	BNAS
(Ontario)
	 
	 
	FedDev to
OBI
	 
	 
	  	 

	 	 
	Cash
	 
	 
	In-kind
	 
	 
	Cash
	 
	 
	Total
	 

	Direct Labour
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 

	Medical Advisor Salary
	 
	 
	34,884	 
	 
	 
	-	 
	 
	 
	 
	 
	 
	34,884	 

	Benefits
	 
	 
	6,977	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	6,977	 

	Post Doc Psychologist
	 
	 
	115,000	 
	 
	 
	-	 
	 
	 
	 
	 
	 
	115,000	 

	Benefits
	 
	 
	23,000	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	23,000	 

	Research Assistant
	 
	 
	88,838	 
	 
	 
	-	 
	 
	 
	 
	 
	 
	88,838	 

	Benefits
	 
	 
	17,768	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	17,768	 

	Project Manager
	 
	 
	-	 
	 
	 
	144,000	 
	 
	 
	 
	 
	 
	144,000	 

	Benefits
	 
	 
	 
	 
	 
	 
	24,480	 
	 
	 
	 
	 
	 
	24,480	 

	Product Lead
	 
	 
	-	 
	 
	 
	170,000	 
	 
	 
	 
	 
	 
	170,000	 

	Benefits
	 
	 
	 
	 
	 
	 
	28,900	 
	 
	 
	 
	 
	 
	28,900	 

	Developers/Software engineering
	 
	 
	-	 
	 
	 
	440,000	 
	 
	 
	 
	 
	 
	440,000	 

	Benefits
	 
	 
	 
	 
	 
	 
	74,800	 
	 
	 
	 
	 
	 
	74,800	 

	Minor & Non Capital Acquisitions
	 
	 
	16,500	 
	 
	 
	-	 
	 
	 
	 
	 
	 
	16,500	 

	Materials and Supplies
	 
	 
	7,890	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	7,890	 

	Professional Services/Professional Fees
	 
	 
	156,990	 
	 
	 
	-	 
	 
	 
	 
	 
	 
	156,990	 

	 	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 

	Access to Intelligym Development Platform
	 
	 
	 
	 
	 
	 
	250,000	 
	 
	 
	 
	 
	 
	250,000	 

	 	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 

	Administrative (goes to OBI)
	 
	 
	 
	 
	 
	 
	-	 
	 
	 
	23,358	 
	 
	 
	23,358	 

	Total
	 
	 
	467,846	 
	 
	 
	1,132,180	 
	 
	 
	23,358	 
	 
	 
	1,623,384	 

 
	 	 
	FedDev
Cash to SK
	 
	 
	BNAS
In-kind
	 
	 
	FedDev
to OBI
	 
	 
	Total
	 

	2012 total
	 
	 
	52,341	 
	 
	 
	250,000	 
	 
	 
	2,617	 
	 
	 
	304,958	 

	2013 total
	 
	 
	216,433	 
	 
	 
	335,790	 
	 
	 
	10,822	 
	 
	 
	563,045	 

	2014 total
	 
	 
	199,072	 
	 
	 
	546,390	 
	 
	 
	9,920	 
	 
	 
	755,381	 

	Project Total
	 
	 
	467,846	 
	 
	 
	1,132,180	 
	 
	 
	23,358	 
	 
	 
	1,623,384	 

 
	Professional Services/Professional Fees
	Project Manager (20% of $90k/yr salary plus 17% benefits billed to project). $100k of software development 33 hours billed at $125/hr per month.

	  	  
	Minor & Non Capital Acquisitions
	Laptops/tablets and software

	  	  
	Materials and Supplies
	Misc supplies as needed

 
	  
	21

	  
	  
	  

 
Project Budget and Timing
 
	 	 
	   Dec 2011-March 2012
	 

	 	 
	Fed Dev -
	 
	 
	BNAS
	 
	 
	Fed Dev to
	 
	 
	  	 

	 	 
	to SK
	 
	 
	(Ontario)
	 
	 
	OBI
	 
	 
	  	 

	 	 
	Cash
	 
	 
	In-kind
	 
	 
	Cash
	 
	 
	Total
	 

	Direct Labour
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 

	Medical Advisor Salary
	 
	 
	5,168	 
	 
	 
	 
	 
	 
	 
	 
	 
	5,168	 

	Benefits
	 
	 
	1,034	 
	 
	 
	 
	 
	 
	 
	 
	 
	1,034	 

	Post Doc Psychologist
	 
	 
	-	 
	 
	 
	 
	 
	 
	 
	 
	 
	-	 

	Benefits
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	-	 

	Research Assistant
	 
	 
	-	 
	 
	 
	 
	 
	 
	 
	 
	 
	-	 

	Benefits
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	-	 

	Project Manager
	 
	 
	 
	 
	 
	 
	-	 
	 
	 
	 
	 
	 
	-	 

	Benefits
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	-	 

	Product Lead
	 
	 
	 
	 
	 
	 
	-	 
	 
	 
	 
	 
	 
	-	 

	Benefits
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	-	 

	Developers/Software engineering
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	-	 

	Benefits
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	-	 

	Minor & Non Capital Acquisitions
	 
	 
	8,639	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	8,639	 

	Materials and Supplies
	 
	 
	-	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	-	 

	Professional Services/Professional Fees
	 
	 
	37,500	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	37,500	 

	Access to Intelligym Development Platform
	 
	 
	 
	 
	 
	 
	250,000	 
	 
	 
	 
	 
	 
	250,000	 

	Administrative (goes to OBI)
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	2,617	 
	 
	 
	2,617	 

	Total
	 
	 
	52,341	 
	 
	 
	250,000	 
	 
	 
	2,617	 
	 
	 
	304,958	 

 
	 	 
	

Total Contributions
	 
	 
	 
	 
	 

	2012 total
	 
	FedDev
	 
	 
	491,204	 
	 
	 
		 
	 
	 
		 

	2013 total
	 
	BNAS
	 
	 
	1,132,180	 
	 
	 
	 
	 
	 
	 
	 
	 

	2014 total
	 
	Total
	 
	 
	1,623,384	 
	 
	 
	 
	 
	 
	 
	 
	 

	Project Total
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 

 
Professional Services/Professional Fees
 
Minor & Non Capital Acquisitions
 
Materials and Supplies
 
	  
	22

	  
	  
	  

 
Project Budget and Timing
 
	 	 
	April-June 2012
	 

	 	 
	Fed Dev -
to SK
	 
	 
	BNAS
(Ontario)
	 
	 
	FedDev to 
OBI
	 
	 
	  	 

	 	 
	Cash
	 
	 
	In-kind
	 
	 
	Cash
	 
	 
	Total
	 

	Direct Labour
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 

	Medical Advisor Salary
	 
	 
	3,876	 
	 
	 
		 
	 
	 
		 
	 
	 
	3,876	 

	Benefits
	 
	 
	775	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	775	 

	Post Doc Psychologist
	 
	 
	15,000	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	15,000	 

	Benefits
	 
	 
	3,000	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	3,000	 

	Research Assistant
	 
	 
	11,588	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	11,588	 

	Benefits
	 
	 
	2,318	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	2,318	 

	Project Manager
	 
	 
	 
	 
	 
	 
	18,000	 
	 
	 
	 
	 
	 
	 
	18,000	 

	Benefits
	 
	 
	 
	 
	 
	 
	3,060	 
	 
	 
	 
	 
	 
	 
	3,060	 

	Product Lead
	 
	 
	 
	 
	 
	 
	21,250	 
	 
	 
	 
	 
	 
	 
	21,250	 

	Benefits
	 
	 
	 
	 
	 
	 
	3,613	 
	 
	 
	 
	 
	 
	 
	3,613	 

	Developers/Software engineering
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	-	 

	Benefits
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	-	 

	Minor & Non Capital Acquisitions
	 
	 
	1,465	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	1,465	 

	Materials and Supplies
	 
	 
	986	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	986	 

	Professional Services/Professional Fees
	 
	 
	14,936	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	14,936	 

	Access to Intelligym Development Platform
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	-	 

	Administrative (goes to OBI)
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	2,697	 
	 
	 
	2,697	 

	Total
	 
	 
	53,944	 
	 
	 
	45,923	 
	 
	 
	2,697	 
	 
	 
	102,564	 

 
	2012 total
	
	2013 total
	
	2014 total
	
	Project Total
	

 
Professional Services/Professional Fees
 
Minor & Non Capital Acquisitions
Materials and Supplies
 
	  
	23

	  
	  
	  

 
Project Budget and Timing
 
	 	 
	July-Sept 2012
	 

	 	 
	FedDev -
	 
	 
	BNAS
	 
	 
	FedDev to
	 
	 
	  	 

	 	 
	to SK
	 
	 
	(Ontario)
	 
	 
	OBI
	 
	 
	  	 

	 	 
	Cash
	 
	 
	In-kind
	 
	 
	Cash
	 
	 
	Total
	 

	Direct Labour
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 

	Medical Advisor Salary
	 
	 
	3,876	 
	 
	 
	 
	 
	 
	 
	 
	 
	3,876	 

	Benefits
	 
	 
	775	 
	 
	 
	 
	 
	 
	 
	 
	 
	775	 

	Post Doc Psychologist
	 
	 
	15,000	 
	 
	 
	 
	 
	 
	 
	 
	 
	15,000	 

	Benefits
	 
	 
	3,000	 
	 
	 
	 
	 
	 
	 
	 
	 
	3,000	 

	Research Assistant
	 
	 
	11,588	 
	 
	 
	 
	 
	 
	 
	 
	 
	11,588	 

	Benefits
	 
	 
	2,318	 
	 
	 
	 
	 
	 
	 
	 
	 
	2,318	 

	Project Manager
	 
	 
	 
	 
	 
	 
	18,000	 
	 
	 
	 
	 
	 
	18,000	 

	Benefits
	 
	 
	 
	 
	 
	 
	3,060	 
	 
	 
	 
	 
	 
	3,060	 

	Product Lead
	 
	 
	 
	 
	 
	 
	21,250	 
	 
	 
	 
	 
	 
	21,250	 

	Benefits
	 
	 
	 
	 
	 
	 
	3,613	 
	 
	 
	 
	 
	 
	3,613	 

	Developers/Software engineering
	 
	 
	 
	 
	 
	 
	25,000	 
	 
	 
	 
	 
	 
	25,000	 

	Benefits
	 
	 
	 
	 
	 
	 
	4,250	 
	 
	 
	 
	 
	 
	4,250	 

	Minor & Non Capital Acquisitions
	 
	 
	1,465	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	1,465	 

	Materials and Supplies
	 
	 
	986	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	986	 

	Professional Services/Professional Fees
	 
	 
	14,936	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	14,936	 

	Access to Intelligym Development Platform
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	-	 

	Administrative (goes to OBI)
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	2,697	 
	 
	 
	2,697	 

	Total
	 
	 
	53,944	 
	 
	 
	75,173	 
	 
	 
	2,697	 
	 
	 
	131,814	 

 
	2012 total
	  
	2013 total
	  
	2014 total
	  
	Project Total
	  

 
Professional Services/Professional Fees
 
Minor & Non Capital Acquisitions
 
Materials and Supplies 
 
	  
	24

	  
	  
	  

 
Project Budget and Timing
 
	 	 
	Oct-Dec 2012
	 

	 	 
	FedDev- to
SK
	 
	 
	BNAS
(Ontario)
	 
	 
	FedDev to
OBI
	 
	 
	  	 

	 	 
	Cash
	 
	 
	In-kind
	 
	 
	Cash
	 
	 
	Total
	 

	Direct Labour
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 

	Medical Advisor Salary
	 
	 
	3,876	 
	 
	 
	 
	 
	 
	-	 
	 
	 
	3,876	 

	Benefits
	 
	 
	775	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	775	 

	Post Doc Psychologist
	 
	 
	15,000	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	15,000	 

	Benefits
	 
	 
	3,000	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	3,000	 

	Research Assistant
	 
	 
	11,588	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	11,588	 

	Benefits
	 
	 
	2,318	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	2,318	 

	Project Manager
	 
	 
	 
	 
	 
	 
	18,000	 
	 
	 
	 
	 
	 
	 
	18,000	 

	Benefits
	 
	 
	 
	 
	 
	 
	3,060	 
	 
	 
	 
	 
	 
	 
	3,060	 

	Product Lead
	 
	 
	 
	 
	 
	 
	21,250	 
	 
	 
	 
	 
	 
	 
	21,250	 

	Benefits
	 
	 
	 
	 
	 
	 
	3,613	 
	 
	 
	 
	 
	 
	 
	3,613	 

	Developers/Software engineering
	 
	 
	 
	 
	 
	 
	45,000	 
	 
	 
	 
	 
	 
	 
	45,000	 

	Benefits
	 
	 
	 
	 
	 
	 
	7,650	 
	 
	 
	 
	 
	 
	 
	7,650	 

	Minor & Non Capital Acquisitions
	 
	 
	1,465	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	1,465	 

	Materials and Supplies
	 
	 
	1,315	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	1,315	 

	Professional Services/Professional Fees
	 
	 
	14,936	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	14,936	 

	Access to Intelligym Development Platform
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	-	 

	Administrative (goes to OBI)
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	2,714	 
	 
	 
	2,714	 

	Total
	 
	 
	54,273	 
	 
	 
	98,573	 
	 
	 
	2,714	 
	 
	 
	155,559	 

 
	2012 total
	  
	2013 total
	  
	2014 total
	  
	Project Total
	  

 
Professional Services/Professional Fees
 
Minor & Non Capital Acquisitions
 
Materials and Supplies 
 
	  
	25

	  
	  
	  

 
Project Budget and Timing
 
	 	 
	Jan-March 2013
	 

	 	 
	FedDev-to
SK
	 
	 
	BNAS
(Ontario)
	 
	 
	FedDev to
OBI
	 
	 
	  	 

	 	 
	Cash
	 
	 
	In-kind
	 
	 
	Cash
	 
	 
	Total
	 

	Direct Labour
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 

	Medical Advisor Salary
	 
	 
	3,876	 
	 
	 
	 
	 
	 
	 
	 
	 
	3,876	 

	Benefits
	 
	 
	775	 
	 
	 
	 
	 
	 
	 
	 
	 
	775	 

	Post Doc Psychologist
	 
	 
	15,000	 
	 
	 
	 
	 
	 
	 
	 
	 
	15,000	 

	Benefits
	 
	 
	3,000	 
	 
	 
	 
	 
	 
	 
	 
	 
	3,000	 

	Research Assistant
	 
	 
	11,588	 
	 
	 
	 
	 
	 
	 
	 
	 
	11,588	 

	Benefits
	 
	 
	2,318	 
	 
	 
	 
	 
	 
	 
	 
	 
	2,318	 

	Project Manager
	 
	 
	 
	 
	 
	 
	18,000	 
	 
	 
	 
	 
	 
	18,000	 

	Benefits
	 
	 
	 
	 
	 
	 
	3,060	 
	 
	 
	 
	 
	 
	3,060	 

	Product Lead
	 
	 
	 
	 
	 
	 
	21,250	 
	 
	 
	 
	 
	 
	21,250	 

	Benefits
	 
	 
	 
	 
	 
	 
	3,613	 
	 
	 
	 
	 
	 
	3,613	 

	Developers/Software engineering
	 
	 
	 
	 
	 
	 
	60,000	 
	 
	 
	 
	 
	 
	60,000	 

	Benefits
	 
	 
	 
	 
	 
	 
	10,200	 
	 
	 
	 
	 
	 
	10,200	 

	Minor & Non Capital Acquisitions
	 
	 
	1,465	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	1,465	 

	Materials and Supplies
	 
	 
	1,315	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	1,315	 

	Professional Services/Professional Fees
	 
	 
	14,936	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	14,936	 

	Access to Intelligym Development Platform
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	-	 

	Administrative (goes to OBI)
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	2,714	 
	 
	 
	2,714	 

	Total
	 
	 
	54,273	 
	 
	 
	116,123	 
	 
	 
	2,714	 
	 
	 
	173,109	 

 
	2012 total
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
	2013 total
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
	2014 total
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
	Project Total
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  

 
Professional Services/Professional Fees
 
Minor & Non Capital Acquisitions
Materials and Supplies  
 
	  
	26

	  
	  
	  

 
Project Budget and Timing
 
	 	 
	April-June 2013
	 

	 	 
	FedDev - to SK
	 
	 
	BNAS 
(Ontario)
	 
	 
	FedDev to
OBI
	 
	 
	  	 

	 	 
	Cash
	 
	 
	In-kind
	 
	 
	Cash
	 
	 
	Total
	 

	Direct Labour
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 

	Medical Advisor Salary
	 
	 
	3,876	 
	 
	 
	 
	 
	 
	 
	 
	 
	3,876	 

	Benefits
	 
	 
	775	 
	 
	 
	 
	 
	 
	 
	 
	 
	775	 

	Post Doc Psychologist
	 
	 
	15,000	 
	 
	 
	 
	 
	 
	 
	 
	 
	15,000	 

	Benefits
	 
	 
	3,000	 
	 
	 
	 
	 
	 
	 
	 
	 
	3,000	 

	Research Assistant
	 
	 
	11,588	 
	 
	 
	 
	 
	 
	 
	 
	 
	11,588	 

	Benefits
	 
	 
	2,318	 
	 
	 
	 
	 
	 
	 
	 
	 
	2,318	 

	Project Manager
	 
	 
	 
	 
	 
	 
	18,000	 
	 
	 
	 
	 
	 
	18,000	 

	Benefits
	 
	 
	 
	 
	 
	 
	3,060	 
	 
	 
	 
	 
	 
	3,060	 

	Product Lead
	 
	 
	 
	 
	 
	 
	21,250	 
	 
	 
	 
	 
	 
	21,250	 

	Benefits
	 
	 
	 
	 
	 
	 
	3,613	 
	 
	 
	 
	 
	 
	3,613	 

	Developers/Software engineering
	 
	 
	 
	 
	 
	 
	60,000	 
	 
	 
	 
	 
	 
	60,000	 

	Benefits
	 
	 
	 
	 
	 
	 
	10,200	 
	 
	 
	 
	 
	 
	10,200	 

	Minor & Non Capital Acquisitions
	 
	 
	1,500	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	1,500	 

	Materials and Supplies
	 
	 
	986	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	986	 

	Professional Services/Professional Fees
	 
	 
	14,936	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	14,936	 

	Access to Intelligym Development Platform
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	-	 

	Administrative (goes to OBI)
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	2,699	 
	 
	 
	2,699	 

	Total
	 
	 
	53,979	 
	 
	 
	116,123	 
	 
	 
	2,699	 
	 
	 
	172,800	 

 
	2012 total
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
	2013 total
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
	2014 total
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
	Project Total
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  

 
Professional Services/Professional Fees
 
Minor & Non Capital Acquisitions
Materials and Supplies
 
	  
	27

	  
	  
	  

 
Project Budget and Timing
 
	 	 
	July-Sept 2013
	 

	 	 
	FedDev -
to SK
	 
	 
	BNAS
(Ontario)
	 
	 
	FedDev
to OBI
	 
	 
	  	 

	 	 
	Cash
	 
	 
	In-kind
	 
	 
	Cash
	 
	 
	Total
	 

	Direct Labour
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 

	Medical Advisor Salary
	 
	 
	3,876	 
	 
	 
	-	 
	 
	 
	-	 
	 
	 
	3,876	 

	Benefits
	 
	 
	775	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	775	 

	Post Doc Psychologist
	 
	 
	15,000	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	15,000	 

	Benefits
	 
	 
	3,000	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	3,000	 

	Research Assistant
	 
	 
	11,588	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	11,588	 

	Benefits
	 
	 
	2,318	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	2,318	 

	Project Manager
	 
	 
	 
	 
	 
	 
	18,000	 
	 
	 
	 
	 
	 
	 
	18,000	 

	Benefits
	 
	 
	 
	 
	 
	 
	3,060	 
	 
	 
	 
	 
	 
	 
	3,060	 

	Product Lead
	 
	 
	 
	 
	 
	 
	21,250	 
	 
	 
	 
	 
	 
	 
	21,250	 

	Benefits
	 
	 
	 
	 
	 
	 
	3,613	 
	 
	 
	 
	 
	 
	 
	3,613	 

	Developers/Software engineering
	 
	 
	 
	 
	 
	 
	90,000	 
	 
	 
	 
	 
	 
	 
	90,000	 

	Benefits
	 
	 
	 
	 
	 
	 
	15,300	 
	 
	 
	 
	 
	 
	 
	15,300	 

	Minor & Non Capital Acquisitions
	 
	 
	500	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	500	 

	Materials and Supplies
	 
	 
	986	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	986	 

	Professional Services/Professional Fees
	 
	 
	14,936	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	14,936	 

	Access to Intelligym Development Platform
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	-	 

	Administrative (goes to OBI)
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	2,649	 
	 
	 
	2,649	 

	Total
	 
	 
	52,979	 
	 
	 
	151,223	 
	 
	 
	2,649	 
	 
	 
	206,850	 

 
	2012 total
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
	2013 total
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
	2014 total
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
	Project Total
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  

 
Professional Services/Professional Fees
 
Minor & Non Capital Acquisitions
Materials and Supplies  
 
	  
	28

	  
	  
	  

 
Project Budget and Timing
 
	 	 
	Oct-Dec 2013
	 

	 	 
	FedDev- to SK
	 
	 
	BNAS (Ontario)
	 
	 
	FedDev to OBI
	 
	 
	  	 

	 	 
	Cash
	 
	 
	In-kind
	 
	 
	Cash
	 
	 
	Total
	 

	Direct Labour
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 

	Medical Advisor Salary
	 
	 
	3,876	 
	 
	 
	 
	 
	 
	 
	 
	 
	3,876	 

	Benefits
	 
	 
	775	 
	 
	 
	 
	 
	 
	 
	 
	 
	775	 

	Post Doc Psychologist
	 
	 
	15,000	 
	 
	 
	 
	 
	 
	 
	 
	 
	15,000	 

	Benefits
	 
	 
	3,000	 
	 
	 
	 
	 
	 
	 
	 
	 
	3,000	 

	Research Assistant
	 
	 
	11,588	 
	 
	 
	 
	 
	 
	 
	 
	 
	11,588	 

	Benefits
	 
	 
	2,318	 
	 
	 
	 
	 
	 
	 
	 
	 
	2,318	 

	Project Manager
	 
	 
	 
	 
	 
	 
	18,000	 
	 
	 
	 
	 
	 
	18,000	 

	Benefits
	 
	 
	 
	 
	 
	 
	3,060	 
	 
	 
	 
	 
	 
	3,060	 

	Product Lead
	 
	 
	 
	 
	 
	 
	21,250	 
	 
	 
	 
	 
	 
	21,250	 

	Benefits
	 
	 
	 
	 
	 
	 
	3,613	 
	 
	 
	 
	 
	 
	3,613	 

	Developers/Software engineering
	 
	 
	 
	 
	 
	 
	90,000	 
	 
	 
	 
	 
	 
	90,000	 

	Benefits
	 
	 
	 
	 
	 
	 
	15,300	 
	 
	 
	 
	 
	 
	15,300	 

	Minor & Non Capital Acquisitions
	 
	 
	-	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	-	 

	Materials and Supplies
	 
	 
	986	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	986	 

	Professional Services/Professional Fees
	 
	 
	14,936	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	14,936	 

	Access to Intelligym Development Platform
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	-	 

	Administrative (goes to OBI)
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	2,624	 
	 
	 
	2,624	 

	Total
	 
	 
	52,479	 
	 
	 
	151,223	 
	 
	 
	2,624	 
	 
	 
	206,325	 

 
	2012 total

	2013 total

	2014 total

	Project Total

 
Professional Services/Professional Fees
 
Minor & Non Capital Acquisitions
Materials and Supplies  
 
	  
	  
	  
	  
	  

 
Project Budget and Timing
 
	 	 
	Jan-March 2014
	 

	 	 
	FedDev - to SK
	 
	 
	BNAS (Ontario)
	 
	 
	  	 
	 
	  	 

	 	 
	Cash
	 
	 
	In-kind
	 
	 
	Cash
	 
	 
	Total
	 

	Direct Labour
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 

	Medical Advisor Salary
	 
	 
	2,584	 
	 
	 
	 
	 
	 
	 
	 
	 
	2,584	 

	Benefits
	 
	 
	517	 
	 
	 
	 
	 
	 
	 
	 
	 
	517	 

	Post Doc Psychologist
	 
	 
	10,000	 
	 
	 
	 
	 
	 
	 
	 
	 
	10,000	 

	Benefits
	 
	 
	2,000	 
	 
	 
	 
	 
	 
	 
	 
	 
	2,000	 

	Research Assistant
	 
	 
	7,725	 
	 
	 
	 
	 
	 
	 
	 
	 
	7,725	 

	Benefits
	 
	 
	1,545	 
	 
	 
	 
	 
	 
	 
	 
	 
	1,545	 

	Project Manager
	 
	 
	 
	 
	 
	 
	18,000	 
	 
	 
	 
	 
	 
	18,000	 

	Benefits
	 
	 
	 
	 
	 
	 
	3,060	 
	 
	 
	 
	 
	 
	3,060	 

	Product Lead
	 
	 
	 
	 
	 
	 
	21,250	 
	 
	 
	 
	 
	 
	21,250	 

	Benefits
	 
	 
	 
	 
	 
	 
	3,613	 
	 
	 
	 
	 
	 
	3,613	 

	Developers/Software engineering
	 
	 
	 
	 
	 
	 
	70,000	 
	 
	 
	 
	 
	 
	70,000	 

	Benefits
	 
	 
	 
	 
	 
	 
	11,900	 
	 
	 
	 
	 
	 
	11,900	 

	Minor & Non Capital Acquisitions
	 
	 
	-	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	-	 

	Materials and Supplies
	 
	 
	329	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	329	 

	Professional Services/Professional Fees
	 
	 
	14,936	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	14,936	 

	Access to Intelligym Development Platform
	 
	 
	-	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	-	 

	Administrative (goes to OBI)
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	1,948	 
	 
	 
	1,948	 

	Total
	 
	 
	39,636	 
	 
	 
	127,823	 
	 
	 
	1,948	 
	 
	 
	169,406	 

 
	2012 total

	2013 total

	2014 total

	Project Total

 
Professional Services/Professional Fees
 
Minor & Non Capital Acquisitions
Materials and Supplies  
 
	  
	29

	  
	  
	  

 
EXHIBIT B: CLAIM STATEMENT FORM

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	  
	30

	  
	  
	  

 
		ONTARIO
BRAIN
INSTITUTE
	TECHNOLOGY DEVELOPMENT PROGRAM
Project Cost Statement
	Period from:
Discover Deliver Period to:
	mm/dd/yyyy
mm/dd/yyyy

 
Converge Discover Deliver
	Project Information:

	Project Name:
	  
	Project Number:
	  
	Address:
	  
	City/Pro vince/Postal Code
	  

 
	Claim Information:

	Data of Invoice
	Cost Category:
	Payment Description:
	Sub-total ($)
	HST (13%)
	Total Amount ($)

	Not-for-profit Expenses

	  	  	  	  	  	  
	  	  	  	  	  	  
	  	  	  	  	  	  
	  	  	  	  	  	  
	  	  	  	  	  	  
	  	  	  	  	  	  
	  	  	  	  	  	  
	  	  	  	  	  	  
	  	  	  	  	  	  
	  	  	  	  	  	  

 
	Industry Expenses/Contributlons

	  	  	  	  	  	  
	  	  	  	  	  	  
	  	  	  	  	  	  
	  	  	  	  	  	  
	  	  	  	  	  	  
	  	  	  	  	  	  
	  	  	  	  	  	  
	  	  	  	  	  	  
	  	  	  	  	  	  
	  	  	  	  	  	  
	  	  	  	  	  	  

 
	  
	31

	  
	  
	  

 
	Not-for-profit Total Claim:
	  	$
	0.00
	  
	For-profit Total Expenses/Contributlons
	  	$
	0.00
	  

 
	Notes:

	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	Additional Information: Additional Payment Deicripticn/ Information can be written here

 
	Signed:______________________________
Authorized Signatory (Not for Profit)
 
Date:________________________________
 
Signed:______________________________
Authorized Signatory (Industry)
 
Date:________________________________
 
Signed:______________________________
Authorized Signatory (Ontario Brain Institute)
 
Date:________________________________ 

 
	  
	32

	  
	  
	  

 
EXHIBIT C: ATTESTATION FORM
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	  
	33

	  
	  
	  

 
		ONTARIO
BRAIN
INSTITUTE
	LABOUR ATTESTATION FORM (Not-for-profit)
	  	  

Converge. Discover. Deliver.
 
Project Number:
 
This letter is provided to confirm that salanes/wages claimed under Claim #_____ for the following individuals have been incurred and paid specific to the project and that the individuals noted below have spent the claimed time solely on the project acti
 
	All expenses claimed have not been reimbursed under any other reimbursement programs be it: Private, Federal, Provincial or other

 
	Employee Name
	Penod From
	Period To
	Hourly Rate
	Hours
Worked
	Wages Claimed
	Benefits*
	Total Amount
	Employee Activities

	  	  	  	  	  	$0, 00
	  	$0 00
	  
	  	  	  	  	  	$0 00
	  	$0.00
	  
	  	  	  	  	  	$0.00
	  	$0 00
	  
	  	  	  	  	  	$0 00
	  	$0 00
	  
	  	  	  	  	  	$0 00
	  	$0 00
	  
	  	  	  	  	  	$0, 00
	  	$0,00
	  
	  	  	  	  	  	$0 00
	  	$0 00
	  
	  	  	  	  	  	$0 00
	  	$0 00
	  
	  	  	  	  	  	$0 00
	  	$0 00
	  
	  	  	  	  	  	$0 00
	  	$0 00
	  
	  	  	  	  	  	$0 00
	  	$0 00
	  
	  	Subtotals
	$0.00
	$0 00
	$0.001

 
* Payroll Fringe Benefits includes employer's share of El, WSIB, health benefits, and other eligible benefits, to a maximum of 20% of gross wages. 
 
	  	 
	Authorized Official
 
 
	Name
 
	Date
 

	  	 
	  	Titile
 
 

 
	  
	34

	  
	  
	  

 
		ONTARIO
BRAIN
INSTITUTE
	LABOUR ATTESTATION FORM (Industry Partner)
	  	  

Converge. Discover. Deliver.
 
Project Number:
 
This letter is provided to confirm that salanes/wages claimed under Claim #_____ for the following individuals have been incurred and paid specific to the project and that the individuals noted below have spent the claimed time solely on the project acti
 
All expenses claimed have not been reimbursed under any other reimbursement programs be it: Private, Federal, Provincial or other
   	Employee Name
	Penod From
	Period To
	Hourly Rate
	Hours
Worked
	Wages Claimed
	Benefits*
	Total Amount
	Employee Activities

						$0, 00
		$0 00
	
						$0 00
		$0.00
	
						$0.00
		$0 00
	
						$0 00
		$0 00
	
						$0 00
		$0 00
	
						$0, 00
		$0,00
	
						$0 00
		$0 00
	
						$0 00
		$0 00
	
						$0 00
		$0 00
	
						$0 00
		$0 00
	
						$0 00
		$0 00
	
		Subtotals
	$0.00
	$0 00
	$0.001

 

	  	 
	Authorized Official
 
 
	Name
 
	Date
 

	  	 
	  	Titile
 
 

 
	  
	35

	  
	  
	  

 
EXHIBIT D: QUARTERLY PROGRESS REPORT FORM
 
Quarterly Reporting Template and Milestones and Activities

TECHNOLOGY DEVELOPMENT PROGRAM

QUARTERLY PROGRESS REPORT
 
Incorporating the "Major Activity Areas" and "Expected Results of the Project" sections of Annex 1 - Statement of Work, the Recipient will report quarterly to the Minister on the progress of the Project, including a percentage of completion for each sub-section within Annex 1 - Statement of Work.
 
Report for the period: __________________________ to_________________________
 
	Recipient:
	«Legal Name»

	Project Number:
	«CMIS_End_Proj No

	» Project Location:
	«Project Location»

 
MAJOR ACTIVITY AREAS
 
	  	Activity Milestones
	  	Percent Complete
	  	On Schedule

	  	  	  	  	  	  
	(Y/N) A)
	  	  	  	  	  
	  	  	  	  	  	  
	B)
	  	  	  	  	  
	  	  	  	  	  	  
	C)
	  	  	  	  	  
	  	  	  	  	  	  
	D)
	  	  	  	  	  
	  	  	  	  	  	  
	E)
	  	  	  	  	  
	  	  	  	  	  	  
	F)
	  	  	  	  	  
	  	  	  	  	  	  
	G)
	  	  	  	  	  

 
If you have answered that any of your Activities are not on schedule, please explain why and offer a proposed new completion date for that Activity(ies)
 
	  
	36

	  
	  
	  

 
EXPECTED RESULTS OF THE PROJECT
 
As per the list of expected results in Annex 1 - Statement of Work, please comment on the following:
 
	  	1.
	$ value of investments (direct expenditures) in the project by source (e.g., federal contribution vs funds leveraged from private sector and other sources)

	  	  	  
	  	2.
	# of partnerships established between NFPs and/or PSIs and private sector enterprises by census division

	  	  	  
	  	3.
	# of partnerships established between NFPs and/or PSIs and private sector enterprises by sector (NAICS code)

	  	  	  
	  	4.
	# of innovations advanced (i.e., # of invention disclosures, # of patent applications)

	  	  	  
	  	5.
	# of person months of employment (both temporary and permanent) created or maintained as a result of TDP funding

	  	  	  
	  	6.
	Total value of sales resulting from innovations developed

	  	  	  
	  	7.
	# of contributions/loans leveraged by TDP-supported collaborations (e.g., private sector, other non-government funding)

	  	  	  
	  	8.
	$ value of contributions/loans leveraged by TDP-supported collaborations (e.g., private sector, other non-government funding)

 
	Please answer the following with each report:
	Yes
	No
	Unsure

	  	  	  	  
	1. Will the Project be complete by [insert date]?
	______
	______
	______

	  	  	  	  
	2. Are all aspects of spending on schedule?
	______
	______
	______

	  	  	  	  
	3. Is there a revised cost forecast?
	______
	______
	______

	  	  	  	  
	4. Would a meeting with a Program Officer be beneficial now?
	______
	______
	______

 
	Signature _________________________________________________________
	Date _____________________________

 
	  
	37

	  
	  
	  

 
EXHIBIT E: FINAL PROGRESS REPORT FORM
 
TECHNOLOGY DEVELOPMENT PROGRAM FORMS OF FINAL REPORT AND FINAL
CERTIFICATE 
FINAL REPORT
 
Upon completion of the Project, please provide a final summary report of the purpose, objectives and benefits, and the results as compared to the information contained in Annex 1 - Statement of Work. The written report should also include information pertaining to the following points:
 
	·
	How has the Project significantly contributed to the development of a globally competitive market- ready technology that has the potential to develop opportunities for businesses and/or benefits to an industry sector, business network, value chain, community or region in southern Ontario

	·
	Describe the financial impact as well as economic and other benefits and measurables as a result of the Project (e.g. project sales, market share, etc.)

	·
	Describe the potential application of the Project Intellectual Property

	·
	Describe measures that have been or will be taken to ensure that any Project Intellectual Property will provide continuing benefits for Southern Ontario

	·
	If not yet commercialized, describe how the Project has brought the technology closer to commercialization; discuss the remaining steps to commercialization

	·
	Will there be future collaborations between the Recipient and the Collaborator(s) in the immediate future or in the long term?

	·
	Will the Recipient or the Collaborator(s) seek collaboration(s) with other parties in a similar manner in the immediate future or in the long term?

	·
	Discuss the impact that the Project has on the strategic direction of the Recipient and the Collaborator(s)

	·
	Provide a summary of the first 3 years of the number of person months of employment that has been created or maintained during the Project and the number of long-term jobs (FTEs) to be created as a result of the project

	·
	Comment on unexpected results, hurdles and considerations

	·
	Is there a potential for future projects to be created as a result of this project?

	·
	Provide the aggregate results based on the Major Activity Areas and Expected Results of the Project, which were reflected in the Quarterly Progress Reports

	·
	Provide any other details or items of interest regarding the Project.

 
	  
	38

	  
	  
	  

Recipient Name:
 
FINAL CERTIFICATE
Application # Project#:
 
	1.
	The Project was completed on ___ (Date)

	  	  
	2.
	Has the Project been successfully completed in accordance with the Statement of Work in Annex 1 of the Contribution Agreement? Yes__ No __

	  	  
	3.
	Have all costs claimed been paid to the suppliers? Yes If no, please provide details: No __

	  	  
	4.
	Have all costs been claimed at actual arm's length cost or at fair market value, net of any refunds or other consideration provided by any supplier? Yes__ No__

	  	  
	5.
	Are there any present or potential liens or claims known to you, which could put the ownership of Project assets at risk? Yes__ No __

	  	  
	If yes, who is this party?-------------------------

	  	  
	6.
	Is the Project in compliance with environment protection measures, which satisfy the requirements of all regulatory bodies of appropriate jurisdiction? Yes__ No__

	  	  
	7.
	Have all special and general conditions stated in the Contribution Agreement been satisfied? Yes__ No__

	  	  
	8.
	Have you disposed of, leased to other parties or ceased to use in the operation any Project assets? Yes__ No__

	  	  
	If
	yes, please describe: __

	  	  
	9.
	Is a final itemized statement of all Project Eligible Costs attached? Yes__ No__

	  	  
	10.
	Is a final statement of all Project costs attached? Yes__ No__

	  	  
	11.
	Is a statement of all funding applied to this Project, including the total government funding received, attached? Yes__ No__

 
	  
	39

	  
	  
	  

 

 
Behavioural Neurological Applications and Solutions
Humanity Together with Technology
100 College Street, Suite 213
Toronto, ON M5G 1L5
July 3, 2014
Hospital for Sick Children
Industry Partnerships & Commercialization
Attention Heidi Falckh
Peter Gilgan Centre for Learning and Research, 3rd Floor
686 Bay Street
Toronto, ON MSG OA4
 
Re: Notice of Exercise of Option
 
This letter shall serve as the Option Exercise Notice as defined under Section IV- Grant Rights in the Collaboration Agreement among the Ontario Brain Institute, The Hospital for Sick Children and Behavioural Neurological Applications and Solutions Inc. which is dated as of December 8, 2011and amended on July 3, 2014.
 
Sincerely,
Scott L. Woodrow, CEO
Behavioural Neurological Applications and Solutions Inc.
scott@ehave.net
(416) 435-9112
 
40ontario_ex1018.htm

EXHIBIT 10.18
 

 
SOFTWARE LICENSE AGREEMENT
 
THIS SOFTWARE LICENSE AGREEMENT (the "Agreement") is made as of December 9, 2014 (the "Effective Date") by and between Pear Therapeutics, Inc. ("Pear"), a Delaware corporation having its principal place of business at 55 Temple Place, Floor 3, Boston MA 02111, and Behavioural Neurological Applications and Solutions Inc. ("Licensor"), having his principal place of business at 100 College Street, Suite 213, Toronto, ON M5G 1L5.
 
WHEREAS Licensor owns and operates a suite of software applications called Megateam, which are software solutions for treating mental health conditions including ADHD (i.e., the Applications);
 
WHEREAS, Licensor licenses the Applications in the form of a software development kit ("SDK"). The SDK is a customized version of the Applications, which includes clinical data tables, clinical data, sample user interface modules, the Application and application program interfaces ("API") to permit third party developers to build bridges or interfaces to communicate with and import and export data to and from the Applications;
 
WHEREAS Pear desires to obtain a license to the Licensor Products in order to allow Pear to embed a customized version of the Licensor Products into its own software and content offerings (i.e., the Pear Application) in order to create Integrated Products for use by healthcare professionals and patients worldwide, subject to the terms and conditions set forth in this Agreement; and
 
WHEREAS Licensor is willing to enter into an agreement with Pear whereby Licensor will provide Pear with a license to the Licensor Products in order for Pear to create Integrated Products and license such Integrated Products to Pear's Users, as well as to provide related services to Pear, including customization of the Applications, support and maintenance services, development services, training, and other professional services, on the terms set forth in this Agreement.
 
NOW, THEREFORE, the parties agree as follows:
 
1. DEFINITIONS.
 
Capitalized terms used but not defined in the body of this Agreement will be as defined in Exhibit A. The meanings given to terms in this Agreement are equally applicable to both the singular and the plural forms of the terms as the context may require.
 
2. LICENSE.
 
2.1 Grant of Licenses. During the License Term and subject to the terms of this Agreement, Licensor hereby grants Pear a worldwide, non-transferable (except as permitted in the Agreement) right and license for Pear to do the following:
 
2.1.1 Create Combination Products: to combine and package the Licensor Products with pharmaceutical drugs, medical foods, and/or food supplements to be marketed as a single product offering as a Combination Product;
 
2.1.2 Commercialize Combination Products: to commercialize and distribute, by way of sublicense to Users, the Combination Product in object code format only, which shall include: (a) the right to use the Content portion of the Licensor Products in Combination Products; and (b) as part of Stand-alone Offerings;
 
2.1.3 Create Integrated Products: to use the source code to the SDK, including the APIs to adopt, modify, utilize, incorporate, embed and/or enhance the Licensor Products for the purpose of creating Integrated Products;   

 
	 
	1

	

	 

 

 
2.1.4 Commercialize Integrated Products: to license, sublicense and distribute to Users the Licensor Products in object code format only as part of and included in any Integrated Products created by Pear, as part of a comprehensive product offering which may include, without limitation, compliance software, medical support, and data outcomes monitoring, as created by Pear;
 
2.1.5 Branding: to create the branding of Integrated Products with marks of Pear's choosing, provided that Licensor is clearly identified as creator of the Applications and Content (e.g., "powered by Licensor" or comparable ingredient branding agreed upon by the parties);
 
2.1.6 Reseller: to distribute, license, sublicense and distribute to Users the Licensor Products in object code format only on a stand-alone basis, including permitting Users to access and use the Content;
 
2.1.7 Sub Distribution: Pear's license rights set out in subsections 2.1.2, 2.1.4 and 2.1.6 include the right for Pear to distribute Licensor Products to its Users directly or indirectly through Pear's distributors, OEMs and resellers; and
 
2.1.8 Clinical Studies: to use the Licensor Products and the Integrated Products in clinical validation studies.
 
The license right granted above to Pear by Licensor will be exclusive (including as to Licensor) with respect to the right granted in Subsection 2.1.2(a) above (i.e., with respect to use of the Licensor Products in connection with the creation of Combination Products), and non-exclusive with respect to all other rights granted to Pear in the Licensor Products under Section 2.1. In addition, all of the foregoing rights granted under Section 2.1 will be permissive but not obligatory; meaning that (unless otherwise expressly set forth in the Agreement to the contrary) Pear will not be under any obligation to use the Licensor Products and/or the Content in any manner whatsoever unless it so chooses.
 
2.2 Restrictions. Except as expressly permitted in this Agreement, Pear will not (and will not permit third parties to):
 
(a) (except as necessary to exercise the rights set forth in Section 2.1, above) distribute, rent, or otherwise transfer any rights in the Licensor Products;
 
(b) except as necessary in the creation of Integrated Products, or pursuant to Section 3.17, modify the Applications. In addition, changes to the Integrated Products that involve further modifications of any customized version of the Applications provided by Licensor will be subject to mutual agreement of the parties, including around the reasonable costs involved to make any such changes;
 
(c) except as permitted by applicable law, reverse engineer, decrypt, decompile, or disassemble the Licensor Products; or
 
(d) use the Licensor Products in any manner or for any purpose not authorized or contemplated by this Agreement.
 
2.3 Limitations on License. Notwithstanding the foregoing, if Pear does not secure the rights to sell Acceptable Drugs in conjunction with the Combination Products, the license granted pursuant to Section 2.1.2(a) will revert to a non-exclusive license.   

 
	 
	2

	

	 

 

 
3. RESPONSIBILITIES OF THE PARTIES.
 
3.1 Responsibilities of Licensor. Licensor will have primary responsibility for performing the following tasks and providing the following services:
 
3.1.1 Delivery. Licensor will deliver the Licensor Products in the manner set forth in Exhibit B. Unless otherwise specified in Exhibit B, or in any amendment hereto, Licensor will deliver all Licensed Products electronically to the location(s) designated by Pear. Suppler will deliver patches, updates, and upgrades to the Licensed Products in accordance with the terms set forth in a separate agreement.
 
3.1.2 Integration. Licensor will work with Pear (for a mutually agreed upon duration of at least 60 days), to integrate the Licensor Products (i.e., the customized version of the Applications into the Integrated Product); both parties will work in good faith to insure that the integration will not materially impact the core operation of the Applications. If, during the foregoing mutually agreed upon integration period, the Licensor Products do not perform in accordance with the applicable specifications therefor, or Pear is unable to integrate the Licensor Products into the Integrated Products, Pear may return the Licensor Products and Licensor will refund to Pear all amounts paid for the such Licensor Products.
 
3.1.3 Clinical Validation. Licensor will provide access to all newly created clinical data involving the Applications as well as, where feasible, access to all existing clinical data. Licensor will also provide services related to further clinical validation of the Applications in combination with drugs. Services shall specifically include the composition of grant applications for clinical validation studies, as well as assistance with any funded clinical validation studies. Costs associated with these activities shall be covered by Pear at reasonable rates to be agreed by both parties.
 
3.1.4 Enhancement Requests. Licensor and Pear shall enter into a separate agreement for any enhancement requests made by Pear.
 
3.1.5 Additional Services. Licensor and Pear shall enter into a separate agreement for any other services requested by Pear.
 
3.1.6 Support and Maintenance. In exchange for the payment of the Support and Maintenance fees set forth in aseparate agreement, if Pear so elects, Licensor will provide Pear with the Support and Maintenance Services (collectively, "Support") more fully described in a separate agreement, which, for greater certainty, shall only consist of Tier 2 background support in relation to the Licensor Products.
 
3.2 Responsibilities of Pear. Subject to the Confidentiality provisions in Exhibit D, Pear will provide Licensor with access to any evaluations, methodology and the data produced through use of the Integrated Products that Pear's partners/licensor allow Pear to access and provide (collectively, "Product Data"); provided that, Licensor may only use such Product Data for Licensor's internal research purposes only. Without limiting the generality of the foregoing, and by way of illustration, (a) Licensor may not use any Product Data to market any end users on behalf of a competitive product or service; (b) the Product Data will not contain any personally identifiable information; and (c) such Product Data will be owned by Pear.
 
3.3 Mutual Obligations of the Parties. Unless agreed by the parties, this Agreement does not set forth any specific service level agreements for customer support. Absent further agreement, Pear will respond to any support requests arising from Users that relate specifically to the Pear Customizations or any Pear functionality or data contained in the Integrated Product. Licensor will provide customer support regarding any and all issues arising from the Licensor Products themselves in accordance with its standard support practices and levels.   

 
	 
	3

	

	 

 

 
4. HIPAA REQUIREMENTS.
 
4.1 Compliance with HIPAA. Licensor acknowledges that any Pear Data transmitted to Licensor hereunder may be subject to federal and state laws, rules and regulations relating to among other subjects, the confidentiality, privacy or security of patient information, including without limitation, the Administrative Simplification Provisions of the Health Insurance Portability and Accountability Act of 1996, Public Law 104-191.45 C.F.R. Part 160, 162, 164 ("HIPAA") and the applicable regulations promulgated thereunder. The parties will at all times comply with the applicable provisions of such laws, rules, and regulations and with the applicable corporate policies and provision of the parties, with respect to the performance of their obligations under this Agreement, with respect to the confidentiality, privacy and security of Protected Health Information ("PHI") and electronic Protected Health Information, as defined in 45 C.F.R. § 164.501 ("ePHI"). For purposes of this Agreement, PHI means individually identifiable information as defined by the Standards for Privacy of Individually Identifiable Health Information, 45 C.F.R. Parts 160 and 164. Cross border data considerations and protocols will be designed by Pear to ensure compliance.
 
5. REQUIREMENTS REGARDING USERS.
 
5.1 User License Agreement. For Combination Products that have a shrink wrap End User License Agreement (an "EULA"), Licensor shall deliver to Pear the required EULA for delivery to the User. Pear shall deliver to the User with each such Combination Product and the appropriate EULA packaged correctly such that the User must perform the necessary steps to agree to the terms of the EULA prior to the User being able to use the Combination Product. For those Combination Products that do not have an associated shrink wrap EULA, Pear shall require the User to execute an EULA, in a form mutually agreed to by Pear and Licensor prior to delivering the Combination Product to the User. In the event that a prospective User desires to amend or change the EULA, such amendments or changes shall require Licensor's prior written approval.
 
5.2 User Information and Reporting. Pear shall obtain from each User such information as required by Licensor from time to time and, if necessary, the consent of such User to collect such information and consent to provide such information to Licensor; provided that, notwithstanding the foregoing, Licensor shall not require any personally identifiable or personal health information. Within ten (10) business days after the end of each calendar quarter and upon the expiration or termination of this Agreement, Pear shall provide Licensor with the required information collected from each End User.
 
5.3 No Representations. Pear shall not:
 
		(i) 	make any representations to any Person regarding the performance and functionality of the Combination Product or Stand-alone Product other than those contained in Licensor's published specifications; or

			
		(ii) 	hold itself out as an agent of Licensor and shall not, nor attempt to, negotiate any contractual arrangement as agent of Licensor, sign any agreement as if it is Licensor or otherwise bind Licensor to any contractual arrangement with a third Person, other than to deliver to an End User an EULA.

 
6. FEES.
 

6.1 License Fees. In consideration of the licenses granted to Pear herein, Pear will pay Licensor the license fees set forth in Exhibit B (the "License Fee").
 

6.2 Reimbursement of Expenses. Pear will reimburse Licensor for all reasonable out-of-pocket expenses incurred by Licensor in performing services under Section 3.15 of this Agreement provided such expenses are approved in writing by Pear in advance. Such out-of-pocket expenses may include: reasonable travel expenses, other than for normal commuting, including airfares, rental vehicles, and highway mileage in company or personal vehicles at the then current IRS approved rate, and meals and lodging. Licensor shall submit an itemized statement of Licensor's expenses due under this Section 6.2, including receipts and other documentation, on a monthly basis. Pear shall reimburse Licensor within forty-five (45) days from the receipt of each statement by Pear.
 

7. STANDARD LEGAL TERMS AND CONDITIONS:The Standard Legal Terms and Conditions governing this Agreement are contained in Exhibit D and incorporated herein by reference
 
	 
	4

	

	 

 

 
IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the Effective Date.
 
	PEAR THERAPEUTICS, INC.;
	 
	LICENSOR:  
	 

	 
	 
	 
	 
	 
	 

	By:
	 
	 
	By:
	 
	 

	Name:
		 
	Name:
		 

	Title:
		 
	Title:
		 

	Date:
		 
	Date:
		 

 
	 
	5

	

	 

 

EXHIBIT A
 
DEFINITIONS
 
"Acceptable Drugs" means a commonly prescribed branded drug acceptable to Licensor, such acceptance shall not be unreasonably withheld.
 
"Applications" means Licensor's applications as described in Exhibit B.
 
"Combination Products" means drug/software combinations, where software is offered as part of apharmaceutical product) (e.g., eFormulations).
 
"Confidential Information" means any and all information disclosed or made available by either party to the other, including orally conveyed information, in connection with this Agreement that is: (a) at the time of disclosure identified or marked as confidential or proprietary information; or (b) by its nature and the circumstances should be considered, or is reasonably obvious to be confidential information. Confidential Information shall be deemed to include the Pear Data, if any, supplied by Pear to Licensor pursuant to this Agreement. Confidential Information does not include any information that the receiving party can demonstrate is: (a) rightfully known prior to disclosure; (b) rightfully obtained from a third party authorized to make such a disclosure, without breach of the terms and conditions of this Agreement or other binding confidentiality obligation; (c) independently developed by the receiving party; (d) available to the public without restrictions; (e) approved for disclosure with the prior written approval of the disclosing party; or (f) disclosed by court order or as otherwise required by law, provided that the party required to disclose the information provides prompt advance notice to enable the other party to seek a protective order or otherwise prevent such disclosure.
 
"Content" means audio and visual information, documents, data and pictures contained in the Applications or made available to Pear in the course of using the Licensor Products.
 
"Integrated Product" means the product resulting from integrating the Licensor Product with a Pear Application. The Integrated Product will constitute a "Pear Wrapper" –i.e., a customized version of the Applications for use by Pear and its Users, with compliance and other layers and allow Users to access software functionality and other data and content contained in the Licensor Products, and will be hosted on servers owned and/or controlled by Pear.
 
"License Term" means the period identified in Exhibit B for which Pear will have access to the Licensor Products.
 
"Licensor IP" means collectively, the Licensor Products made available to Pear by Licensor under the Agreement, including any source code, know-how, and clinical data related to the Applications, and all trademarks licensed by Licensor to Pear under the Agreement.
 
"Licensor Products" means collectively, the SDK and Content, as further described in E x hib it B .
 
"Pear Application" means a Pear-owned, proprietary software application, including any future releases, updates, or upgrades thereto.
 
"Pear Customizations" means any proprietary scripts, macros, modules or software developed by Pear or Licensor to customize Pear's use of, or access to, the Licensor Products.
 
"Pear Data" means any data, information or material that Pear and/or Pear's Users submit to or receive from the Licensor Products in the course of Users using the Integrated Products, as well as all clinical data from clinical studies involving any Pear resources.   

 
	 
	6

	

	 

 
 
 
 
"Pear IP" means collectively, the Pear Application; the Pear Customizations; the Pear Data; Pear trademarks; and the Pear-Owned Property, as well as any and all improvements to all licensed IP, and improvements to source code thereunder.
 
"Pear-Owned Property" means all tangible and intangible items or information that Licensor receives from Pear or from a third party on Pear's behalf, or that is paid for by Pear, including but not limited to Pear Data and Pear Customizations.
 
"Person" means any individual, corporation, partnership, limited liability company, association, unincorporated association, trustee, trust or other entity or organization.
 
"Source Code" means the human-readable language form of the software code that comprises (in object code form) the Licensor Products, together with any build tools (e.g., compilers, linkers and other related tools), compile/link scripts, logic diagrams, program comments, installation scripts and other documentation and tools necessary for an ordinarily skilled programmer to understand and be able to address errors in or create ports, updates or other modifications to such software code, or to recompile the same into fully functioning object code of the applicable Licensor Products.
 
"Stand-alone Offerings" means software content, designed for use in combination with a particular pharmaceutical, but sold alone (i.e., outside of Combination Products' packaging).
 
"Users" means any Person who Pear, either directly or indirectly, authorizes to use the Combined Product, Integrated Product or Licensor Products, through an EULA.   

 
	 
	7

	

	 

 

    

EXHIBIT B – LICENSE SCHEDULE
 
LICENSE TERMS AND FEES
 
This License Schedule sets forth the terms and conditions for a license for the use of the Licensor Products, as identified below. Except as modified by this License Schedule, the terms and conditions of the Agreement govern the license to the Licensor Products.
 
(1) LICENSE TERM.
 
The license term begins on the Effective Date of the Agreement and will continue in perpetuity unless terminated in accordance with the express terms of the Agreement (the "License Term").
 
(2) DESCRIPTION OF LICENSOR PRODUCTS.
 
The Applications shall consist of only the following software modules:
 
Megateam Attention and Working Memory Assessment and Remediation System consisting of: (a) Game World;
 
(b) Stop Signal Assessment Task Assessment (Inhibitory Control); (c) Working Memory Assessment;
 
(d) Attention Training Game; and
 
(e) Working Memory Training Game.
 
(3) UPGRADES.
 
All upgrades, updates, bug fixes, improvements, corrections, enhancements, and major and minor releases to the Licensor Products (collectively, "Upgrades") will be delivered and installed, if applicable, according to the terms of the Agreement, at no additional cost to Pear. Licensor will provide sufficient testing instructions and description of the new functionality or features of all Upgrades to ensure its successful implementation. Any Upgrades shall be deemed to be Licensor Products for purposes of this Agreement and are hereby automatically licensed to Pear subject to the terms and conditions of this Agreement.
 
(4) FEES.
 
A) License Fees. In connection with the licenses granted in this Agreement, Pear will pay
 
Licensor as follows:
 
Fees will be paid via the following revenue sharing arrangement: a royalty equal to 2.5% of Net Revenue from the (i) license of Integrated Products; (ii) license of Combination Products, and (iii) license of the Licensor Products on a Stand-alone Basis, utilizing the Licensor Products during the Term. Pear will provide payments to Licensor on a quarterly basis. Pear will provide reports along with license payments hereunder in sufficient detail to illustrate the basis for the payments made, if applicable. "Net Revenue" means amounts actually received by Pear from the license of Users of Integrated Products and/or Combination products utilizing the Licensor Products and/or Licensor Products on a Stand-alone Basis during the Term less the following: (i) customary trade, quantity, or cash discounts; (ii) amounts repaid or credited by reason of rejection or return; (iii) any taxes or other governmental charges; (iv) transportation costs prepaid or allowed and costs of insurance in transit; and (v) commissions, and other costs of goods sold.   

 
	 
	8

	

	 

 

 
B) Support and Maintenance. Will be set forth in a separate agreement.
 
(5) THIRD PARTY PRODUCTS
 
Megateam is built on a Unity platform. A Unity Developer License is required for patches, updates, upgrades and enhancement.
 
(6) DELIVERY.
 
x Within 10 days of the Effective Date, Licensor will provide Pear a link to a cloud locker containing the Licensor Products. In providing of Support, Licensor will make maintenance releases and Upgrades available to Pear on a web site designated by Licensor and accessible using FTP protocols. C) Clinical Validation Fees. The fees payable by Pear to Licensor for clinical validation and consulting services (the "Clinical Validation Fees") shall be set out in a mutually acceptable Statement of Work provided to Pear pertaining to clinical services, upgrades or other requested services. Each Statement of Work will include, but not be limited to, the following items: (i) scope of services, necessary requirements, assumptions, dependencies and obligations of each party. Pear acknowledges that each Statement of Work may require an upfront retainer fee in such an amount that is mutually agreeable. Pear shall not unreasonably withhold consent or agreement relating to the foregoing matters.   

 
	 
	9

	

	 

 
 

    
EXHIBIT C
 
Intentionaly! omitted.   

 
	 
	10

	

	 

 
 
EXHIBIT D
 
Standard Legal Terms and Conditions
 
1. Ownership.
 
1.1 Title to Licensor Products. Pear acknowledges that title to the Licensor IP made available to Pear by Licensor under this Agreement is and will remain the sole property of Licensor. Pear acknowledges that it has no proprietary interest in or right to use the Licensor IP except in accordance with the terms of the licenses granted in this Agreement.
 
1.2 Title to Pear IP. Subject to its underlying rights in the Licensor Products, Licensor acknowledges that title to the Pear IP is and will remain the sole property of Pear. Without limiting the generality of the foregoing and by way of illustration only, Licensor acknowledges that it has no proprietary interest in or right to use the Pear Data or the Pear-Owned Property except in accordance with the express terms of this Agreement.
 
1.3 Assignment. To the extent that Licensor has or at any time acquires any right, title or interest in or to any Pear Data, Integrated Products, Pear Customizations or any other Pear IP, Licensor hereby assigns all of such right, title and interest, including all copyrights, patents and other intellectual property rights, in and to such Pear IP to Pear. On request from Pear, Licensor shall execute any documents necessary to confirm and perfect Pear's ownership of the Pear IP, at no additional cost to Pear.
 
2. Confidentiality. Neither party will use any Confidential Information of the other party except as expressly permitted in this Agreement or as expressly authorized in writing by the other party. Each party shall use the same degree of care to protect the other party's Confidential Information as it uses to protect its own Confidential Information of like nature, but in no circumstances less than reasonable care. Neither party is allowed to disclose the other party's Confidential Information to any person or entity other than the receiving party's officers, employees, consultants and legal advisors who need access to such Confidential Information to effectuate the intent of the Agreement and who are subject to confidentiality obligations with such party. Each party agrees to notify the other of any unauthorized use or disclosure of Confidential Information and to provide reasonable assistance to such other party, and its licensors, in the investigation and prosecution of such unauthorized use or disclosure. All Pear-Owned Property shall be deemed the Confidential Information of Pear. Without limiting the generality of the foregoing, Licensor does not own any Pear Owned Property and may not use or disclose any Pear-Owned Property except as expressly provided in this Agreement. Licensor shall have sole responsibility for maintaining the accuracy, quality, integrity, reliability, and confidentiality of all Pear-Owned Property transmitted to Licensor in Pear's use of the Licensor Products. Licensor shall be responsible for the deletion, destruction, damage, loss or failure to store any Pear-Owned Property sent to Licensor under this Agreement.
 
3. Warranties. Licensor represents and warrants each of the following:
 
3.1 Title. Licensor has and will have good, marketable and unencumbered title to the Applications and the Licensor Products.
 
3.2 Performance. The Licensor Products, and any upgrades, enhancements, new releases, or updates thereto, shall perform in accordance with all specifications and documentation, and be free from material or frequent errors; provided however, that the foregoing warranty will not apply to the extent the Licensor Products are modified by Pear in an authorized manner or used beyond the scope of the licenses granted in this Agreement.   

 
	 
	11

	

	 

 

 
3.3 Non-Infringement. Neither the Licensor Products, the use thereof, nor Pear's exercise of its rights under this Agreement, will not infringe, misappropriate or otherwise violate any intellectual property right worldwide or other right of any third party worldwide, including property, contractual, employment, copyright, patent, trade secret, trademark, or nondisclosure rights.
 
3.4 Other Licenses. The performance of this Agreement and Pear's use of the Licensor Products will not require any license to use the intellectual property of a third party, except as otherwise expressly set forth on Exhibit B, as applicable. If any part of the Licensor Products contains third-party software, Licensor has the full power and authority to sublicense the third-party software as part of its license grant to Pear hereunder, and such use by Pear hereunder will not require additional licenses to be obtained and/or fees to be paid by Pear.
 
3.5 No Viruses. The Licensor Products will be free from any viruses, worms, disabling programming codes, instructions or other such items that may threaten, infect, damage, disable or otherwise interfere with the permitted use of the Licensor Products ("Virus"). If Pear notifies Licensor that it has been informed or has reason to believe that a Virus has infected Pear computer or server, Licensor will promptly assist and work continuously with Pear, at Pear's direction and at no charge, until, in Pear's determination, the Virus has been eliminated.
 
3.6 Malicious Technology. The Licensor Products will not: (i) contain any Malicious Technology, (ii) contain any files or features that will disable or destroy any functionality of the Licensor Products, (iii) monitor Pear's or its Users' use of the Integrated Products; (iv) replicate, transmit or activate itself without control of a person operating the computing equipment on which it resides; or (v) alter, damage or erase any data or computer programs without control of a person operating the computing equipment on which it resides. If the Licensor is in breach of this Section, no "right to cure" period will apply. Pear reserves the right to pursue any available civil or criminal action against Licensor for violation of this provision. Licensor will not install, use or execute any software on any Pear CPUs without Pear's written approval. "Malicious Technology" means any software, electronic, mechanical or other means, device or function , e.g. (key node, lock, time-out, "back door," trapdoor," "booby trap," "drop dead device," "data scrambling device," "Trojan Horse,") that would allow Licensor or a third party to: (i) monitor or gain unauthorized access to any Pear system, (ii) use any electronic self-help mechanism or (iii) restrict, disable, limit or impair the performance of a Pear system or network.
 
3.7 Compliance with Laws. Licensor will comply with all applicable laws, orders, codes and regulations in the performance of this Agreement, including, if applicable, those regarding privacy and security of protected health information. Licensor warrants that it has not at any time been disbarred or excluded from participation in any federal healthcare program, nor is Licensor under investigation or consideration for such disbarment or exclusion. Licensor will obtain and keep current at its expense all governmental permits, certificates and licenses (including professional licenses, if applicable) necessary for Licensor to grant the licenses under this Agreement. Licensor will proactively and cooperatively work with and assist Pear in a timely manner to ensure that the Licensor Products have been effectively tested and complies with all legal requirements prior to or contemporaneously with the effective date of such legal requirements.
 
3.8 Good Standing. Licensor (i) is validly existing and in good standing, and is qualified to do business, in each jurisdiction where it will conduct business under this Agreement; (ii) the signing, delivery and performance of this Agreement by the party has been properly authorized; and (iii) no claims, actions or proceedings are pending or, to the knowledge of the party, threatened against or affecting the party that may, if adversely determined, reasonably be expected to have a material adverse effect on the party's ability to perform its obligations under this Agreement.   

 
	 
	12

	

	 

 

 
3.9 Open Source. Licensor complies with Open Source Licenses for software embedded in the Licensor Products or otherwise used or incorporated in the Licensor Products and has not and shall not use such software licensed under Open Source Licenses in a manner that will cause or could reasonably cause Contamination of Customer's technology in providing the licenses to the Licensor Products under the Agreement. "Contamination" means that proprietary technology has become subject to the terms of an Open Source License under which downstream recipients or other third parties may claim the right to (a) copy, create derivative works of, or redistribute the proprietary technology, or (b) receive the source code of the proprietary technology. "Open Source License" means a software license under which source code is made available under terms allowing a licensee to copy, create derivative works and distribute the software without fee or cost.
 
3.10 Breach of Warranty; Remedy. If there is a breach of any of the foregoing warranties, Licensor will promptly replace and/or repair nonconforming Licensor Products at Licensor's sole cost. If Licensor fails to promptly replace and/or repair nonconforming Licensor Products to Pear's reasonable satisfaction, Pear may, in addition to exercising any other available remedies, replace or repair nonconforming Licensor Products at Licensor's sole cost and/or terminate the license and receive a refund for any fees paid for the nonconforming Licensor Products prior to such point of termination.
 
4. Indemnification.
 
4.1 Indemnification. Licensor shall indemnify and hold harmless Pear and its affiliated entities, and all of their trustees, officers, directors, shareholders, legal representatives, customers, partners, employees, successors, assigns and agents from and against any and all claims, proceedings, damages, injuries, liabilities, losses, costs and expenses (including reasonable attorneys fees and litigation expenses) based on or arising from: (a) any claim or allegation that the Licensor Products infringe any intellectual property right or other proprietary right of any third person, (b) any injury to or death of any person or damage to tangible, personal or real property to the extent caused by Licensor's negligence or willful misconduct in the course of its performing services under this Agreement; (c) any violation of applicable law by Licensor; or (d) any breach or alleged breach by Licensor of this Agreement, including any of its representations, warranties or obligations set forth in this Agreement. Pear will give Licensor prompt notice of any such claim or allegation or the commencement of any litigation against Pear to which the above indemnification obligation applies, provided that Pear's failure to give such notice shall not relieve Licensor of any of its obligations under this Section except to the extent that Licensor is actually prejudiced by such failure. Pear shall fully cooperate with Licensor in the defense of such claim. Except as required by law, Licensor shall conduct the defense and any settlement negotiations in any such third-party action arising as described herein using experienced counsel reasonably acceptable to Pear, provided, Licensor shall not compromise or settle any claim in a manner which affects Pear's rights, makes admissions on Pear's behalf or obligates Pear to take or not take any action, including without limitation the payment of money, without Pear's prior written approval, which shall not be unreasonably withheld or delayed.
 
4.2 Disruption of Use of Licensor Products. If a third-party claim causes Pear's quiet enjoyment and use of the Licensor Products and/or Integrated Products to be endangered or disrupted, Licensor shall, at Pear's sole option: (a) replace the Licensor Products, without additional charges, with a functionally equivalent and non-infringing product; or (b) modify the Licensor Products to avoid the infringement; or (c) obtain a license for the Pear to continue use of the Licensor Products and pay for an y additional fee required for such license. If none of these are feasible to Pear's reasonable satisfaction, Pear will be entitled to terminate this Agreement and, in addition to any other remedies it may have under this Agreement or at law, will receive a refund for moneys previously paid for the affection portions of the Licensed Products.   

 
	 
	13

	

	 

 

 
5. LIMITATION OF LIABILITY. EXCEPT IN THE EVENT OF BREACH OF ITS CONFIDENTIALITY OBLIGATIONS, OR WITH RESPECT TO EITHER PARTY'S INDEMNIFICATION OBLIGATIONS, OR IN THE EVENT OF A BREACH BY LICENSOR OF ITS EXCLUSIVITY OBLIGATIONS IN SECTION 2, IN NO EVENT WILL EITHER PARTY BE LIABLE TO THE OTHER FOR ANY INDIRECT, PUNITIVE, EXEMPLARY OR CONSEQUENTIAL DAMAGES, OR DAMAGES ON ACCOUNT OF LOSS OF PROFITS OR FAILURE TO ACHIEVE ANTICIPATED REVENUES, EVEN IF SUCH DAMAGES WERE WITHIN THE CONTEMPLATION OF THE PARTIES. EXCEPT FOR IN CONNECTION WITH EITHER PARTY'S INDEMNIFICATION OBLIGATIONS, OR A BREACH OF ITS CONFIDENTIALITY OBLIGATIONS, OR IN THE EVENT OF A BREACH BY LICENSOR OF ITS EXCLUSIVITY OBLIGATIONS IN SECTION 2, IN NO EVENT WILL EITHER PARTY'S TOTAL AGGREGATE LIABILITY FOR ALL CLAIMS ARISING OUT OF THIS AGREEMENT EXCEED THE AMOUNT PAID OR PAYABLE BY PEAR UNDER THIS AGREEMENT PRIOR TO THE EFFECTIVE DATE OF THE NOTICE OF ANY SUCH CLAIM. THIS PROVISION APPLIES REGARDLESS OF HOW THE LIABILITY AROSE OR THE THEORY OF LIABILITY, INCLUDING WITHOUT LIMITATION CONTRACT OR TORT (INCLUDING PRODUCTS LIABILITY, STRICT LIABILITY, NEGLIGENCE AND MISREPRESENTATION).
 
6. Term And Termination.
 
6.1 Term. The initial term of this Agreement begins on the Effective Date and will continue for the duration of the License Term (the "Term"), unless terminated sooner in accordance with this Section 6.
 
6.2 Termination by Licensor. Licensor may terminate this Agreement if:
 
(i) Pear has not paid USD$4,000,000 annual royalties to Licensor for each of fiscal calendar years 2022, 2023 and 2024; and
 
(ii) Pear has not obtained appropriate regulatory approvals resulting in the right to commercialize the Combination Products and/or the Integrated Products within eight (8) years of the Effective Date.
 
6.3 Termination for Material Breach. If a party materially breaches this Agreement, the other party must give the breaching party a material breach notice, identifying the action or inaction that is the basis of the breach. The party giving the breach notice may terminate this Agreement if the other party does not cure the breach to the reasonable satisfaction of the non-breaching party within thirty (30) days after receiving the breach notice. No breach under this Agreement will constitute a breach under any other agreement, license or schedule between the parties. Unless otherwise provided in the breach notice or unless the breach has been cured to the reasonable satisfaction of the non-breaching party, the termination is effective thirty-one (31) days after the breach notice is given. In addition to any other rights or remedies that Pear may have, if Pear terminates under this Section, Licensor must reimburse Pear for the increased costs incurred by Pear for replacement services or products.
 
6.4 Change in Control of Licensor. Pear may, at any time and without liability, terminate this Agreement, if a person or entity previously not in control of Licensor acquires, directly or indirectly, control of Licensor, or in the event of a purchase or sale of all or substantially all of the assets, stock, or business operations of Licensor. Licensor must give Pear no less than one hundred and twenty (120)-days' notice of any change in control or sale of Licensor, unless prohibited by applicable laws. Unless otherwise provided in the notice, the termination is effective ten (10) days after Pear gives the termination notice, if applicable.
 
6.5 INTENTIONALLY DELETED.
 
6.6 Insolvency. If Licensor becomes Insolvent, Pear may terminate this Agreement without liability and without notice to Licensor. "Insolvent" means: (i) Licensor does not meet its undisputed obligations, including judgments, to third parties as those obligations become due, (ii) Licensor's stock is removed or delisted from a trading exchange, (iii) Licensor's long term debt goes on a watch or warning list, or (iv) Licensor's long term debt rating is downgraded more than two (2) levels from its debt rating as of the Effective Date.   

 
	 
	14

	

	 

 

 
6.6 Termination Without Cause. Pear may at any time without cause terminate this Agreement upon at least sixty (60) days written notice to Licensor.
 
6.7 Effect of Termination. Termination of this Agreement is without prejudice to any other right or remedy of the parties. Termination of this Agreement for any reason does not release either party from any liability which, at the time of termination, has already accrued to the other party, or which may accrue in respect of any act or omission prior to termination or from any obligation which is expressly stated to survive the termination.
 
6.8 Post-Termination Obligations. Upon termination of this Agreement, the parties will perform the following obligations:
 
(A) Within fifteen (15) days after the effective date of termination or expiration, Licensor will return Pear Owned Property to locations designated by Pear;
 
(B) Within thirty (30) days after the effective date of termination or expiration, Licensor will invoice Pear for any final amounts accrued prior to the effective date of termination under the Agreement;
 
(C) Within one hundred twenty (120) days after the effective date of termination or expiration, Pear will terminate availability of access to the Integrated Products that are utilizing the Licensor Products (or any approved modified version thereof); provided that any previously granted end user licenses to the Integrated Products and/or Stand-alone Offerings shall survive according to their terms. The parties will mutually agree on mechanisms for Licensor to monitor such cessation, which may include a license validation system incorporated into the Integrated Product, and the right to monitor App Store listings; and
 
(D) Both parties will immediately discontinue making any statements or taking any actions that might cause third parties to infer that a business relationship continues to exist between the parties under the Agreement, and where necessary or advisable, the parties will inform third parties that the parties no longer have a business relationship.
 
7. Audit. Licensor may, at its expense and upon ten (10) business days prior written notice, audit such records, documentation or files, including financial records and documentation, of Pear that evidence compliance by Pear of this Agreement, including the calculation and remittance of the appropriate fees. Any such audit shall be conducted during regular business hours at Pear's facilities and shall not unreasonably interfere with Pear's business activities. Pear shall provide reasonable assistance to Licensor in the conduct of the audit. If an audit reveals that Pear has underpaid any fees to Licensor, Pear shall be invoiced for the difference between the fees to be paid as determined by the audit and the actual fees paid by Pear. If the difference between the fees to be paid as determined by the audit and the actual fees paid by Pear exceed ten percent (10%) of the actual fees paid by Pear, then Pear shall also pay Licensor's costs of conducting the audit. Audits shall be conducted no more than once annually, unless an audit reveals an underpayment by Pear, in which case an audit may be conducted again by Pear at any time upon five (5) business days prior written notice.   

 
	 
	15

	

	 

 

 
8. Miscellaneous.
 
8.1 Notice. Notices provided under this Agreement must be in writing and delivered by (i) certified mail, return receipt requested, (ii) hand delivered, (iii) facsimile with receipt of a "Transmission OK" acknowledgment, (iv) e-mail, or (v) delivery by a reputable overnight carrier service (in the case delivery by facsimile or e-mail the notice must be followed by a copy of the notice being delivered by a means provided in (i), (ii) or (v)). The notice will be deemed given on the day the notice is received. In the case of notice by facsimile or e-mail, the notice is deemed received at the local time of the receiving machine, and if not received, then the date the follow-up copy is received. Notices must be delivered to the following addresses or at such other addresses as may be later designated by notice:
 
	Pear:
	 
	Licensor:

	Corey McCann
	 
	Scott Woodrow

	55 Temple Place, Floor 3 
	 
	100 College Street, Suite 213 

	Boston, MA 02111
	 
	Toronto, ON M5G 1L5

	Email: cmccann@peartherapeutics.com 
	 
	Email:scott@ehave.net

 
8.2 Assignment. This Agreement shall be binding upon and inure to the benefit of the parties hereto, their successors, assigns, and legal representatives. Except as otherwise set forth in this Agreement, Pear will not assign any of the licenses granted to it under the Agreement in whole or in part without Licensor's prior written consent; provided however that notwithstanding the foregoing, (i) Pear may assign this Agreement to any successor to its business, including by a purchase or sale of all or substantially all of the assets, stock or business operations, any change of control, acquisition, merger or consolidation of Pear into, by, or with another entity, or any other transfer by operation of law; and (ii) Pear may hire or contract with third parties of its choice to assist it in fulfilling its obligations and exercising any of its rights pursuant to this Agreement, provided that Pear will remain liable for the subcontractor's performance. Licensor may not assign, or otherwise transfer this Agreement, any right granted or obligation imposed hereunder, in whole or in part, without Pear's prior written consent.
 
8.3 Access to Books and Records. To the extent that Section 952 of P.L. 96-499 (42 U.S.C. Section
 
1395x(v)(1)) is applicable to this Agreement, the parties agree as follows: (a) until the expiration of four (4) years after the furnishing of such services pursuant to this Agreement, each party shall make available, upon written request of the Secretary of the U.S. Department of Health and Human Services or upo n request of the Comptroller General of the United States, or any of his/her duly authorized representatives, this Agreement, and books, documents and records of such party that are necessary to certify the nature of the duties of this Agreement; and (b) if either party performs its services hereunder through a subcontract with a value of cost of Ten Thousand Dollars ($10,000) or more over a twelve (12)-month period, then any such subcontract shall contain a clause to the effect that until the expiration of four (4) years after the furnishing of such services pursuant to such subcontract, the related organization shall make available, upon written request of the Secretary of the U.S. Department of Health and Human Services or upon request of the Comptroller General of the United States, or any of his/her duly authorized representatives, the subcontract, and books, documents and records of such organization that are necessary to verify the nature and extent of the cost of services provided pursuant to such subcontract.
 
8.4 Governing Law. This Agreement shall be governed, interpreted and enforced under and in accordance with the laws of the Commonwealth of Massachusetts, excluding its conflicts of law provisions. Each party submits to the exclusive jurisdiction of and forum in the state and federal courts located in Suffolk County, Commonwealth of Massachusetts.
 
8.5 Unenforceability. Should any of the provisions of this Agreement be found illegal or unenforceable in any respect, such illegality or unenforceability shall not affect the other provisions of the Agreement, all of which shall remain enforceable in accordance with their terms. Any unenforceable provisions shall be replaced by an enforceable provision effecting the intention of the parties, as determined by the tribunal of fact.
 
8.6 Currency. All amounts are stated and payable in United States dollars.   

 
	 
	16

	

	 

 

 
8.7 Survival. The following sections of the main body of the Agreement and of this Exhibit D will survive expiration or termination of this Agreement for any reason: Section 4 of the main body of the Agreement ("HIPAA Requirements"); and Sections 1 ("Ownership"), 2 ("Confidentiality"), 3 ("Warranties"), 4 ("Indemnification"); 5 (Limitation of Liability); 6.6 ("Effect of Termination"), 6.7 ("Post-Termination Obligations"), 7 (Audit) and 8 (Miscellaneous) of this Exhibit D.
 
8.8 Use of Name. Nothing in this Agreement grants Licensor the right to use any trademarks, trade names or logos proprietary to Pear. If Licensor is granted a right to use such marks, Licensor will do so only in strict compliance with Pear guidelines provided by Pear. All goodwill associated with any use of Pear trademarks will inure to Pear.
 
8.9 Remedies. All rights and remedies of the parties, under this Agreement, in law or at equity, are cumulative and may be exercised concurrently or separately. The exercise of one remedy will not be an election of that remedy to the exclusion of other remedies.
 
8.10 Applicability of Laws. Each party will comply with all applicable export laws, obtain any applicable export licenses and will not export or re-export any part of the Licensor Products to any country in violation of such restrictions, or any country that may be subject to an embargo by the United States. Prior to providing Pear with any Licensor Products subject to export control laws, Licensor will notify Pear and identify such items and the applicable export control laws, and will furnish to Pear the applicable Export Control Classification Numbers.
 
8.11 Public Announcements. Neither party will make any public announcement regarding the business relationship of the parties or this Agreement without the other party's prior express written permission, unless required by law; in which case, the disclosing party will provide the other party as much advance written notice as reasonably possible. Notwithstanding the foregoing, Pear will be entitled, without Licensor's prior consent, to publically disclose the fact of the partnership contemplated by this Agreement, but not the specific commercial terms of the Agreement.
 
8.12 Entire Agreement. This Agreement, including Exhibits, all of which are attached, constitute the entire Agreement and understanding between Licensor and Pear concerning the subject matter hereof, and supersedes and terminates all prior written and oral agreements, proposals, promises, and representations of the parties respecting the Service covered by this Agreement. In the event of any conflict or ambiguity between any Exhibit and the terms and conditions set forth in this Agreement, the terms and conditions in this Agreement shall control.
 
 
17

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00251-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00251-of-00352.parquet"}]]